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Cysteine Based PNA (CPNA): 
Design, Synthesis and Application 
 
Sung Wook Yi 
 
 Abstract 
 
 
 
This report mainly discusses the development of the cysteine based PNA (CPNA), which 
is an analogue of PNAs. Peptide nucleic acids (PNA), a pseudopeptide DNA mimic, was 
discovered by Nielsen and his coworker in 1991. PNA is proved to sequence-specifically form a 
very stable duplex with complementary DNA and RNA strands through Watson-Crick base paring, 
and it is also capable of binding to duplex DNA by helix invasion. These intriguing properties of 
PNA implicated great potential for medical and biotechnical applications. Therefore, PNA has 
attracted many scientists in the fields of chemistry, biology, medicine including drug discovery 
and genetic diagnostics, molecular recognition. Due to its acyclic, achiral and neutral nature of 
the backbone, PNA has shown problems such as its poor aqueous solubility, poor cell 
permeability and instability of PNA-DNA duplexes and triplexes. Accordingly, many synthetic 
approaches have been directed toward developing modified backbones of PNA. Among those 
PNA analogs, only few examples including lysine-based monomers, guanidine-based peptide 
nucleic acids (GPNA) and the aminoethylprolyl PNA (aep-PNA) showed noticeable 
enhancements with regards to the daunting challenges mentioned above. Reported herein is the 
summary of our research endeavor to develop the CPNA oligomers with the great water-solubility 
and cell permeability. Chapter one briefly summarizs the background and history of the PNA as 
the front-runner of the antisense therapeutic agents. Chapter two discusses the novel protocols 
  xii 
 
 
that enabled synthesis of the various versions of CPNA monomers for both Fmoc and Boc solid 
phase synthesis strategies. Chapter three includes the experimental procedures for solution 
phase preparation of the CPNA monomers. Chapter four starts with the introduction of solid 
phase synthesis strategy. After the brief review, our efforts on solid phase based synthesis of 
CPNA oligomers are discussed. Detailed procedures for the solid phase synthesis are 
summarized in Chapter five. Disclosed In the final chapter is a methodology which enables 
regioselective mono-acylation of  hydrazines. Remarkably, this new protocol gives the mono-
acylation on the less-reactive nitrogens of the hydrazines. Carbon disulfide takes the key role for 
this unique transformation. At the end of the dissertaion, selected NMR and Mass spectra are 
attached. 
  1
 
 
 
 
 
1. Chapter One:  An Introduction to the Properties and Applications of PNA and why 
CPNA: Cysteine Based PNAs are Important New Advances. 
1.1. Introduction. 
 
 Peptide nucleic acids (PNA), first discovered in 1991 by Nielsen, Egholm, Berg and 
Buchardt, is a pseudopeptide DNA mimic, which replaces the phosphate ribose ring backbone of 
DNA with a N-(2-aminoethyl) glycine polyamide backbone1. In spite of the fact that PNAs have a 
very different structure, they have shown the capability of sequence specific binding to DNA as 
well as RNA. 
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Figure 1: Structure of DNA and PNA. 
 
Moreover, their complexes with complementary DNA or RNA have proven to be extremely stable2. 
Due to their extraordinary binding properties and stability, PNA is considered as a promising 
reagent for antigene and antisense therapies as well as gene diagnostics.3 In this chapter, the 
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properties of PNA as well as its applications are detailed as to put chapters 2 and 4 in context. In 
addition, the limitations that PNAs have faced and the approaches to overcome those barriers are 
discussed in the later stage of this chapter. At the end of this chapter, the backbone of the 
cysteine based PNA will be disclosed with our rationale for the design of the PNA. 
 
1.2. DNA: structure and its properties. 
1.2.1. Structure of DNA. 
 
 Since PNA was designed as a DNA mimic, and its applications are directly related to the 
structure and function of DNA, it is necessary to understand the nature of DNA. 
 
 
Figure 2: Chemical structure of DNA4 
 
 Deoxyribonucleic acid, DNA, is a long polymer made from repeating units called 
nucleotides. 5  The backbone of the DNA strand consists of alternating phosphate and 2-
deoxyribose residues6 and a base is attached to the sugar in its unit. In DNA, four bases are 
  3
found and they are called adenine (often abbreviated as A), cytosine (C), guanine (G) and 
thymine (T). These four bases are attached to the sugar/phosphate backbone to form the 
complete nucleotide. James Watson and Francis Crick revealed the double helix molecular 
structure of the DNA In 1953, and nine years later, they shared the Nobel Prize in Physiology or 
Medicine with Maurice Wilkins for solving one of the most important of all biological riddles7. In 
living organisms, DNA normally exists in the shape of a double helix. The DNA double helix is 
stabilized by hydrogen bonds between the bases, hydrophobic effects and pi stacking.8  Unlike 
the complementary base paring, the latter factors stabilizing the double helix are not influenced 
by the sequence of the DNA.  
 
 
Figure 3: Structures of A, B and Z DNAs.4 
 
 Due to the fact that two complementary bases are tied with the weak hydrogen bonding, 
the two DNA strands can be pulled apart and rejoined relatively easily. Indeed, this reversible 
interaction between the complementary base pairs is essential in DNA replication and critical for 
its other functions9.  
 
  4
1.2.2. Function of DNA. 
 
 DNA normally occurs as linear chromosomes in eukaryote cells, and circular 
chromosomes in prokaryote cells. The set of chromosomes in a cell makes up its genome and 
the human genome has about 3 billion base pairs of DNA arranged into 46 chromosomes10. DNA 
carries the information held in the sequence of pieces of DNA called genes. Transmission of 
genetic information in genes is accomplished via complementary base pairing. For example, in 
transcription, when a cell utilizes the information in a gene, the sequence of the DNA is copied 
into a complementary RNA sequence through the attraction between the DNA and the correct 
RNA nucleotides. Usually, this RNA copy is then used to make a matching protein sequence in a 
process called translation, which can also be described as protein biosynthesis. Alternatively, a 
cell may simply copy its genetic information in a process called DNA replication. RNAs and their 
properties will be discussed with more details in a section as part of this chapter.  
 
1.2.2.1. Transcription of DNA. 
 Transcription is the process that synthesizes RNA under the direction of DNA. The DNA 
sequence is enzymatically copied by RNA polymerase to produce a complementary nucleotide 
RNA strand, called messenger RNA (mRNA)11. One notable difference between RNA and DNA 
sequences is the presence of uracyl (U) in RNA instead of the thymine (T) of DNA. In the case of 
protein-encoding DNA, transcription is the first step that usually leads to the expression of the 
genes, by the production of the mRNA intermediate, which is a transcript of the gene's protein-
building instruction. The stretch of DNA that is transcribed into an RNA molecule is called a 
transcription unit. A transcription unit that is translated into protein contains sequences that direct 
and regulate protein synthesis in addition to coding the sequence that is translated into protein. 
The regulatory sequence that is before, or 5' of the coding sequence, is called the 5' untranslated 
(5'UTR) sequence, and the sequence found following, or 3' of the coding sequence, is called the 
3' untranslated (3'UTR) sequence. Transcription has some proofreading mechanisms, but they 
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are fewer and less effective than the controls for copying DNA; therefore, transcription has a 
lower copying fidelity than DNA replication11. As in DNA replication, transcription proceeds in the 
5' to 3' direction. Only one of the two DNA strands is transcribed and this strand is called the 
template strand, because it provides the template for ordering the sequence of nucleotides in an 
RNA transcript. The DNA template strand is read 3' to 5' by RNA polymerase and the new RNA 
strand is synthesized in the 5' to 3' direction. RNA polymerase binds to the 5' end of a gene 
(promoter) on the DNA template strand and travels toward the 3' end. Except for the fact that 
thymines in DNA are represented as uracils in RNA, the newly synthesized RNA strand will have 
the same sequence as the coding (non-template) strand of the DNA. For this reason, scientists 
usually refer to the DNA coding strand that has the same sequence as the resulting RNA when 
referring to the directionality of genes on DNA, not the template strand. Transcription is divided 
into 3 stages: initiation, elongation and termination. These three steps will not be discussed in 
detail. Once the DNA is transcribed to mRNA the next step is to translate the genetic information 
from the mRNA into the proteins using the nutrients and fuel provided. The translating process 
will be briefly discussed later in this chapter.  
 
1.2.2.2. DNA replication. 
 The process of copying a double-stranded DNA molecule is called DNA replication and it 
is essential in all living organisms. Generally, the mechanisms of DNA replications in prokaryotic 
and eukaryotic organisms are somewhat different, and some antibiotics take advantage of those 
different mechanisms. The basic mechanism of DNA replication became clearer when the 
complementary, double-stranded structure of DNA was recognized by Watson and Crick in 
19537,5. Although the replication of the DNA is one of the most important biological processes, it 
is beyond the scope of this dissertation to discuss in detail.  
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1.2.2.3. Structure of RNA and translation. 
 Like DNA, RNA is a nucleic acid made from nucleotide units. This long chain of 
nucleotides has a nitrogenous base, a ribose sugar, and a phosphate in its unit. It structurally 
differs from DNA. RNA is usually single stranded in the cell in contrast to the double stranded 
DNA. Of course, the hydroxyl group in ribose is the functional group that makes the difference. In 
addition, RNA nucleotides contain uracils instead of thymines, which are found in DNA.5,11 There 
are many types of RNA found in the cell, but it is beyond the scope of this section to discuss all of 
them and their functions in this report. Among all the RNAs, the messenger RNA (mRNA) is the 
one that carries the specific information from DNA to the ribosome for production of a protein in a 
process called translation. Translation can be simply called protein biosynthesis and this 
important process is the part of the gene regulation that is proceeded by transcription. The 
genetic information from chromosomes is carried by the mRNA, and the information is recorded 
as a ribonucleotide sequence, which is read by the translational machinery in a sequence of 
nucleotide triplets. These triplets of nucleotides are called codons and many of them have unique 
functions. For example, a codon codes for a specific amino acid and a codon also can be a 
specific order for an action in translation.12  
 
1.3. Antisense Therapy. 
1.3.1. Introduction to antisense therapy. 
 
 Antisense refers to short sequenced oligonucleotides that have a complementary 
sequence to a mRNA. At present, antisense therapy is an emerging trend in biotechnology. This 
trend was initiated after the understanding of the mechanism of gene expression and is powered 
by the Human Genome Project (HGP), which was completed in 2003 when the approximately 
25,000 genes in human DNA were sequenced.13 
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Figure 4: The basic principles of the antisense approach. 
 
 The idea of antisense therapy is outlined in Figure 4. About 20 to 25 bases containing 
nucleotides of DNA or RNA can bind to a specific messenger RNA (mRNA), which can 
subsequently prevent protein synthesis.14  Likewise, other molecules that sequence specifically 
bind to mRNA can target gene related diseases by preventing expression of the targeted protein. 
Summarized here in Figure 5 is an overview of families of antisense agents.15  
 
1.3.2. DNA and RNA oligonucleotides as antisense therapeutic agents. 
 
 As discussed briefly before, DNA and RNA oligonucleotides can be great therapeutic 
agents. However, a couple of studies reported the stability problems of these oligonucleotides in 
biological system. 16  The unmodified phosphodiester backbone of antisense 
oligodeoxynucleotides (ODNs) is rapidly degraded in biological systems. Like DNA, unmodified 
RNA has also shown its instability in the biological environments.17 Moreover, the cellular uptake 
of antisense DNA and RNA oligonucleotides in cultured cells is very poor. These combined 
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inconvenient truths could not diminish scientists’ passion for the idea of the antisense therapy.  
The various strategies to overcome these problems are summarized in the next section. 
 
1.3.3. The endeavor to overcome the inconvenient truths of antisense therapeutic agents. 
1.3.3.1 Modification of the backbones of the oligonucleotides. 
 As it is discussed before, the DNA and RNA oligonucleotides have poor bioavailability 
and delivery problems as antisense therapeutic agents. To increase the stability for the 
therapeutic applications the backbone of the oligonucleotides has been extensively modified. 
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Figure 5: Analogues of ODNs.  
 
 First, the phosphorothioate (PS) ODNs18 were widely studied as the representative of first 
generation modified oligonucleotides. Peptide nucleic acids (PNAs), 19 2’-methoxyethyl based 
ODNs,20 morpholino-based ODNs21 and locked nucleic acids (LNA) are considered as second 
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generation in this category. The representations of the structural variation of modified versions of 
ODNs are illustrated in Figure 5.  
 Similar to DNA, since unmodified RNA showed instability, various backbone 
modifications have been done to increase the stability of ribozymes while retaining its catalytic 
activity. 22  2’-O-methyl ribonucleotides, 23  chimeric RNA-phosphorothioate DNA, 24  and 3’-3’-
inverted thymidines at the 3’ termini25 are the representative analogues that are partially replaced 
in the ribozyme to preserve catalytic activity.26 The structures of modified backbones of the RNA 
are represented in Figure 6. 
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Figure 6: Modified backbones of RNA. 
 
 In summary, the endeavor to enhance the plasma stability of the oligonucleotides by 
modifying the backbones has shown some positive improvements, but in terms of improving their 
cellular uptake, the available modifications have solved the intracellular delivery issues. 
 More recently, the phenomenon of RNAi has gained substantial attention from the world 
of antisense therapy after Andrew Fire and Craig Mello introduced double-stranded (ds) RNA to 
inhibit targeted unc-22 RNA gene, producing severe twitching movements in the worm.27  In 2006, 
Fire and Mello won the Nobel Prize for their work which began in 1998. The mechanism of RNA 
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interference is conceptually similar to antisense but the RNA appears to play the key role for the 
process is double stranded RNA (dsRNA) or siRNA, so it is technically a little different than the 
mechanism of traditional antisense mechanisms. 
 In contrast to the approaches that directly modify the DNA/RNA nucleotides, there are 
indirect ways to overcome the barriers that possible antisense agents must overcome. An 
alternate method is the conjugation of the antisense oligomers with other molecules as aids for 
the delivery. Among other possible methods, conjugating the oligomers with lipids, 28 
dendrimers,29 biodegradable polymers30 or cell penetrating peptides31 are the strategies that are 
commonly used to deliver the antisense agents to the targets. 
 
1.4. PNA: structure, property and application. 
1.4.1. Structure and properties of PNA. 
 
 According to the article, which disclosed PNA for the first time in 1991, it was designed by 
computer-assisted modeling by building a normal TAT triplex.1 The deoxyribose phosphate 
backbone of the third (the T) strand was removed and a polyamide backbone was built to replace 
the original backbone. Surprisingly, the resulting polyamide nucleic acids proved to be a good 
structural mimic of the ribose phosphate backbone of nucleic acids. Consequently, PNA 
immediately attracted scientists with wide interests because it had great potential as a gene 
therapeutic agent or as a tool for genetic diagnostics. 
 
  11
H2N N
A O
O
H
N N
C O
O
H
N N
G O
O
H
N N
T O
NH2
O
DNA
O
O P
O
O
O
O
O P
O
O
O
O
O P
O
O
O
O
O
T G C A
HO
P
O
O
OH
PNA
 
Figure 7: Structures of PNA and DNA backbones. 
 
 The structure of the PNA backbone is completely changed so it looks little like a ODN 
and more like a peptide. It certainly has polyamide backbone, however technically it is not peptide 
because the basic unit is no longer an amino acid. As early as the 1970s, De Koning and Pandit 
disclosed a class of nucleopeptides derived from lysine, 32  and Buttrey et al. prepared the 
polymers of thyminyl-β-alanine.33 However, these oligomers of nucleobase amino acids did not 
hybridize to polyA efficiently; subsequently the application towards the antisense technology 
could not be extended further.34 Nonetheless, the aminoethyl glycine based PNA presented great 
binding properties to DNA as well as RNA, and this result revived the world of antisense 
therapeutics one more time.35 
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a) Triplex b) Triplex invasion c) Duplex Invasion d) Double Duplex Invasion
 
Figure 8: PNA binding modes for targeting double stranded DNA.  
(Bold structure signifies the 10mer PNA and Blue line represents Watson-Crick base paring). 
 
 PNAs have shown that a mimic of DNA/RNA do not have to rely on the backbones of the 
DNA and/or RNAs. According to a study which was reported by Nielsen,35 the reason why the 
PNA is a good mimic of DNA can be explained by the favorable geometry of the backbone 
combined with a structure of constrained flexibility. This allows the oligomer to adapt to the helical 
structure preferred by DNA or RNA without losing the entire gain in binding enthalpy in decreased 
entropy upon formation of the much more rigid duplex or triplex structures. His explanation could 
be supported by the study that was reported in 1996.36 In that report, they removed the rigidity 
imposed by the planar amide by reducing the amide linker and the DNA binding properties of the 
PNA with the reduced backbone was detrimental. Therefore, a certain degree of the rigidity in 
PNA backbone is important for the DNA/RNA binding. More structural studies with regards to 
their binding properties shall be discussed in the section that addresses the analogues of PNA. 
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 Originally, PNA was designed with the expectation that it could bind to DNA to make a 
triplex; however, it was observed that PNA binds to DNA duplex by triplex invasion.37 A single 
PNA can bind to the DNA duplex by duplex invasion38 although with less efficiency. In addition, 
when alternative pseudo complementary nucleobases (such as the 2,6-diaminopurine-2-
thirouracil) were used, PNA can make very stable complexes by double duplex invasion.38 In 
Figure 8, binding modes of PNA to DNA duplex are illustrated.  
 
 
Figure 9: Structures of various PNA complexes. 
 
 At present, NMR and X-ray crystallography have determined four three-dimensional (3-D) 
structures of PNA complexes. As shown in Figure 9, the structures illustrated in the top panel are 
the representation of views from the side as compared to the views from the top, which are in 
lower panel. The PNA-RNA39 and PNA-DNA40 duplex structures were solved by NMR methods 
while the PNA2DNA triplex 41  and PNA-PNA 42  duplex structures were determined by X-ray 
crystallography. The studies have shown that PNA is able to adapt to its partner relatively well. In 
terms of sugar puckering, the PNA-RNA duplex structure is close to DNA’s natural A-
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conformation while the PNA-DNA duplex adopts close to B-conformation. Interestingly, PNA in 
other structures prefers a unique helix form, the P-form, which can be seen in the PNA-PNA 
duplex while PNA2DNA triplex structure is a unique-form. 
 
1.4.2 PNA application. 
 
` The fascinating DNA and RNA hybridization properties of PNA have gained great 
attention because it has such a potential for various medical purposes. As it is discussed earlier, 
it is a contender for antisense therapy due to its excellent binding properties although exploitation 
of PNA to the antisense world is hampered by its inefficient cellular uptake in most eukaryotic 
cells. 43  Its sequence specific DNA/RNA binding properties can be readily applied to gene 
diagnostic technologies such as in situ hybridization, 44  “pre-Southern” blotting, 45  array 
hybridization, 46 modulation of PCR analyses 47 and tools for genome mapping. 48 It has been 
reported that PNA could arrest transcription sequence specifically by binding the template 
strand,49 which suggests that it may also be used as an antigene therapeutic agent. 
 
 
1.5. PNA analogues and derivatives. 
 
 The structure of the original PNA monomer has been subjected to rational modification 
with the expectation of understanding the structure activity relationships in this class of antisense 
and/or antigene agents as well as with the aim of improving the properties of oligomers to 
overcome the problems of intracellular delivery. The major problems include low aqueous 
solubility, ambiguous DNA binding orientation and poor membrane permeability.50  
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1.5.1. Rationales for modification of PNA. 
 
 To solve the problems associated with using standard PNA mentioned earlier, PNA could 
be structurally modified in different ways. It could be the ethylendiamine or glycine sector that 
undergoes transformation. The linker to the nucleobases can also be modified. In fact, the 
nucleobase itself can be a factor.  
 Strategically, the common rationale for the modification of PNA can be categorized as 
follows. The strategic rationales behind the structural PNA modification are listed. First, 
introducing chirality to the backbone of PNA to gain the orientational selectivity in complementary 
DNA binding. Secondly, increasing the rigidity of the backbone to entropically drive PNA to the 
duplex formation. Third, introduction of cationic functional groups directly in the PNA backbone 
somehow to potentially increase intracellular delivery. Fourth, modulating base pairing by 
changing the linker to either the nucleobase or the nucleobase itself. Lastly, conjugating the PNA 
with a molecules that could deliver it into the targeted cells. These changes are necessary to use 
PNAs for mainly therapeutic purposes. In addition, PNA has been modified to optimize its 
diagnostic applications. 
 
1.5.2. Structural modification of PNA backbone. 
 
 The early attempts to modify the PNA involve the simple extension of the original PNA 
backbone, which is the aminoethyl glycine unit or the base linker. The earliest and the simplest 
modified PNA backbones are grouped as the first generation and illustrated in Figure 10. I 
represents the classic backbone reported in 1991. Then, simply extending parts of the backbone 
gave II51, III 52 and IV52 respectively, however all of these attempts resulted in a significantly 
lowering of melting points (Tm) of the derived PNA-DNA hybrids. When replacing the carbonyl 
group of the tertiary amide it gives the tertiary amine in the backbone, which is V,53 and this 
flexible or less rigid and cationic backbone resulted in destabilization of the PNA-DNA hybrid. 
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This result suggested that a certain degree of the rigidity in the backbone is necessary for 
hybridization properties of PNA. Further modifications of the PNA backbone were directed in a 
way to gain the rigidification of the backbone by introducing alkyl substituents on the backbone. 
These attempts are summarized in Figure 11.  
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Figure 10: The first generation of modified PNA 
 
VII54 shows the template that can substitute the alkyl group on either side of the backbone or on 
the both sides. A number of the modifications, which replaced the glycine component with other 
amino acids, consequently leads to chiral PNA VII when R1 is hydrogen. The PNAs with R2 group 
include both hydrophobic and hydrophilic group, and even charged alpha substituted groups54C 
have been reported. PNA oligomers with the chiral monomers showed the retention of the 
hybridization properties with a little less efficiency. Small and medium substituents at the alpha 
position of the glycine were reported to exhibit tolerance. However, among other replacements, 
only those derived from D-lysine showed DNA binding properties as good as that of classical 
PNA.54 Even a cyclohexyl ring is corporated into the backbone with different approaches to give 
VIII55 with the 1,2-cyclohexylamino group and IX56 with the spirocyclic hexyl group. These trials 
though did not improve PNA’s DNA binding properties. 
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Figure 11: Second Generation of modified PNA. 
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Figure 12: PNAs with the chiral backbones. 
 
 By interchanging of various carbonyl and NH groups on the peptide linkages, different 
types of PNAs(X,57 XI58 and XII59) have been generated. All these systems exhibited a lower 
potency for duplex formation with the complementary DNA/RNA implying that in addition to the 
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geometric factors, other subtle changes or factors may influence the PNA-DNA or PNA/RNA 
hybridization. 
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Figure 13: More analogues of the PNA backbone. 
 
 XIII 60  represents the early strategy that using alpha-amino acids carrying 
nucleobase building blocks that reported even before PNA was introduced. These nucleopeptides 
did not have significant interaction with polynucleotides. A study to incorporate XIII and XIV in one 
oligomer was reported, but the result was not encouraging.61 Adenylic analogues of PNA derived 
from XV, which were interspersed with the glycine, serine, threonine or tyrosine exhibited strong 
binding properties with poly (dT) and poly (U) to form triplexes.62 PNA oligomers derived from 
alternating monomers of XVI, XVII, XVIII and XIX with the type XIII and other amino acids have 
been reported without any enhanced properties.63 
 Although with much weaker affinity, PNAs derived from XX with glycine and alanine linker 
showed very high sequence specificity.64 Glucopyranosy PNA (GNA)65 derived from XXI have 
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shown its RNA binding affinity equivalent to that of DNA-RNA hybridization but with much better 
specificity.  
Tetramers of XXII which have a aromatic moiety in the backbone showed favorable bas 
stacking interactions66 while the olefin PNAs67 derived from XXIII had less affinity toward DNA 
which indicates that the importance of amide bond for its electrostatic effects.  PNA analogues 
based on XXIV, XXV and XXVI which, replace the amide to phosphonic acid,68 phosphoamide69 
and phosproroamide70 respectively, have shown interesting DNA duplexation properties with the 
excellent water-solubility due to the negative charges on their backbones. 
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Figure 14: The backbones of aep-PNA and other analogues. 
 
The chimerical PNAs, which are derived from alternating monomers of PNA and DNG (XXVII) 
have been reported71.  These PNA-DNG oligomers have shown great binding properties with 
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DNA and RNA. Similarly, PNAs with the XXVIII72 as the alternating monomer have also been 
reported. PNAs from monomers derived from XXIX73 also have shown relatively positive results 
with its flexibility to interchange the position of the nucleobase and backbone among the different 
nitrogens. 
 Three monomers XXX,73 XXXI74 and XXXII75 have cyclic ring systems on the backbone. 
While oligomers of XXXI have shown negative results due to the extreme rigidity of the tertiary 
amide with the ring system, PNAs derived from XXX and XXXII have shown promising results. 
Especially the latter one, the N-(2-aminoethyl) prolyl (aep) PNA, is considered as one of the most 
successful analogues because it has shown an unprecedented affinity towards DNA strand with 
the great discriminating power and at least 25 times better aqueous solubility than the original 
PNAs. Oligomers from XXXIII and XXXIV have been reported76 with some good results. However, 
these backbones are closer to that of DNA than PNA. 
 
1.5.3. Structural modification of nucleobases. 
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Figure 15: Structure of Main Nucleobases. 
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 There has been a steady stream of reports in modulating and expanding the recognition 
motif of standard base pairs to better understand the recognition process in the world of 
nucleotides chemsitry.50 Compared to the efforts of backbone modification, not many non-
standard nucleobases has been employed in the PNA or oligonucleotides scaffolds. The limited 
studies on the modification of the nucleobases have reported some interesting results.77 The 
structures of the modified the nucleobases have been summarized in Figure 16 along with the 
standard nucleobases (Figure 15) for the comparison. In short, these approaches could provide 
very useful information concerning the binding properties of DNA analogues as well as the 
applications in diagnostic and nanomaterial chemistry. 
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Figure 16: The non-standard nucleobases. 
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1.6. Cysteine Based PNA(CPNA). 
 
 Improving the bioavailability of potential drugs is the one of the major challenges for drug 
discovery and PNAs have been facing these common problems. Despite all the modifications 
from different angles, the development of PNAs with the therapeutic applications is still being 
hampered by cellular uptake and delivery problems. PNAs have been successful so far in gene 
diagnostics, however, it is too early to be satisfied with the progress that PNAs have made.  
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Figure 17: Analysis of the cysteine based PNA backbone. 
 
 By carefully analyzing the data from the earlier studies, a new backbone of the PNA was 
designed and developed. As it is shown in Figure 17, this backbone consists of a cysteine and an 
aminoethyl group. Cysteine is a chiral amino acid that has a highly nucleophilic thiol group.  Most 
of time, this functional group has to be protected when one needs to do chemical transformations 
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on the other functional groups. This explains the reason why the cysteine has rarely been 
involved with the modification of PNA  by other groups. We have envisioned that the thiol group 
can add many positive aspects as part of the PNA backbone in many ways. The 
aminoethylcysteinyl backbone ideally meets many of the criteria that have been applied for 
modifying the backbone of PNA. First, as a chiral amino acid, cysteine can provide the PNA the 
chirality so the complementary DNA/RNA binding could have selective orientation. Second, Its 
additional alkyl group moderately increases the rigidity of the backbone compared to that of 
classical PNA. It could provide the cationic functional group. In fact, by utilizing the nucleophilicity 
of thiol, we can put a library of other functional groups in that position. In addition, the flexibility in 
terms of modulating the size of the alkyl group and the type of alkyl group is unprecedented. 
Furthermore, when designing the alkyl groups that are going to be attached to the backbone, the 
rationales have been adapted to increase the aqueous solubility of the oligomers as well to 
increase the cell permeability. The rationales for the design were developed after studying the 
peptides that are reported to penetrate the cells78, which are very inspiring. 
 Our synthetic endeavor to complete the backbone as well as the oligomer synthesis 
using solid phase chemistry is discussed in the following chapters. 
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2. Chapter Two: Synthesis of Cysteine based PNA Monomers. 
2.1. Introduction. 
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Figure 18: Comparison of the units for Peptide, PNA and CPNA. 
 
 PNA oligomers are polyamide compounds but they are not peptides because their 
building blocks are not amino acids 79 . However, since they have polyamide bonds in their 
backbones, PNA oligomers are constructed by methods similar to those of peptides. In most 
cases, application of solid phase chemistry is necessary for their construction and their 
monomers are prepared with orthogonal protecting groups on both the C and N termini. 
Discussed herein is our work to prepare the cysteine based PNA monomers with different 
protecting groups. The synthesis of PNA oligomers will be discussed in chapter three.  Notably, 
since the newly designed backbone contains cysteine residues, synthesis protocols of the 
monomers has to allow 3 sites to be protected before each termini is reacted. In other words, our 
cysteine based PNA (CPNA) have C, N and S termini in one building block that require protection. 
Therefore the preparation of the monomers was not trivial. Figure 18 shows differences in their 
structures between peptides, regular PNAs and our cysteine based PNAs. 
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2.2. CPNA sub-monomers with acetonide protecting on N, S- termini. 
 
 When we began this project, our main goal was to improve the physical properties of 
PNA oligomers by adding charged alkyl groups on the S-termini. Moreover, it was also 
anticipated that the native peptide ligation effect80 of the thiol group could well be adapted for the 
solid phase synthesis of the resulting CPNAs.  So we developed a scheme for the monomers that 
are protected with acetonide for the N, S-termini and methyl ester for the C-termini. Scheme 1 
presents the protocol to develop the Boc protected sub-monomers.  
 
Scheme 1: Boc protected sub-monomers. 
 
  
 Synthesis of the first sub-monomer for the project started out with HCl salt of L-cysteine. 
The first reaction in the procedure that was reported in 1958 provided us 1 with excellent yield. 
The semi-protected compound 1 was then protected with Boc anhydride to give compound 2. The 
yield of the second step was normally reported to give poor yield. Among the precedented 
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a
  31
procedures, the best reported yield for this reaction was 60 %. Several attempts from our 
laboratory to reproduce or match the best yield weren’t satisfactory and our best result was 40 % 
which matches with the recently reported work from other groups81, 82. The next step was a 
Weinreb amide83 formation to give 3 with 70 percent yield. A reduction of 3 using DIBAL-H gave 
aldehyde 4 which was then directly subjected to a reductive amination to give 5. The combined 
yield for the last two steps was 69 percent. So the first sub-monomer for the CPNA project was  
 
Scheme 2: Synthesis of Fmoc sub-monomers 11, 12. 
 
 
obtained after the 5-step procedure with overall yields of 17.8 %. Although it was manageable to 
get grams of 5, we weren’t so enthusiastic on this protocol. Thereafter, we decided to try Fmoc 
group instead of the Boc group for the protection of the N-terminus. The change of the protecting 
group gave us exciting results as shown in Scheme 2. The esterification of the starting material 
using thionyl chloride in MeOH gave the 6 which was then semi-protected with acetonide to give 
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784. The yields of the first two steps were 95% and 85%, respectively. The base-labile Fmoc 
group was then introduced to 7 to give 8 with 83% yield. First three steps gave us 8 with 
combined yield of 67% which was considerably better than the 37% overall yield of compound 2 
(see the Scheme 1). The next step was to reduce the methyl ester to the corresponding aldehyde 
10. Even though there are known procedures to directly reduce 8 using DIBAL-H at -78 ˚C, it was 
the practical decision for us to follow the 2-step protocol which gave us consistent results with a 
good combined yield. Reduction of 8 using DIBAL-H at 0 °C gave us the primary alcohol 9 with 
91% yield. Oxidation of 9 with Dess-Martin Periodinane (DMP) afforded us 10 with a good yield. 
The somewhat unstable aldehyde 10 was directly subjected to a reductive amination reaction with 
the two different glycine esters. With the methyl glycine ester, the reaction gave us 11 with 80% 
which was slightly better than that of 12.  
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2.3. Nucleo base coupling on the sub-monomers. 
 
Scheme 3: Synthesis of acetic acid derivatives of nucleo bases 14, 15 and 16. 
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Scheme 4: Optimization of the coupling condition for the CPNA monomers. 
 
 
With the sub monomers in hand, we needed to couple the nucleo bases to the backbone. As it 
was shown in Chapter One, nucleo bases are connected to the PNA backbone through an acetyl 
linker. Only thymine acetic acid is commercially available and other nucleo bases have to  
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be manually prepared to have the linker and the proper protecting groups. Scheme 3 shows our 
first generation of the bases that are prepared for the coupling onto the CPNA backbones. In fact, 
the compounds 15, 16 and 17 are not fully protected because we thought that the amines on the 
bases are not as nucleophilic as ordinary amines on our backbones so it wouldn’t  be necessary 
for the coupling steps to fully protect the bases. The simple procedures to make acetic acid 
derivatives of nucleo bases are known85,86 and shown in Scheme 3.  
 
Scheme 5: Cbz protected A and C derivatives. 
 
 Scheme 4 briefly presents the conditions we tried to couple our sub-monomers and the 
acetic acid derivatives of the nucleo acids. Presumably due to the structural nature of our sub-
monomers, ordinary coupling procedures with 13 using DCC and EDC had given us 
unsatisfactory results. However, a trial of the amide formation using HATU in DMF with TEA gave 
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didn’t give the desired monomers. The problem with coupling the unprotected adenine and 
cytosine derivatives was the insolubilities of the derivatives in variours organic solvents. To solve 
the problem, we decided to protect the adenine (A) and cytosine (C) derivatives with the Cbz 
group. The Cbz protected adenine and cytosine derivatives were prepared by the reported 
procedure86 which is described in the Scheme 5.  
 
2.4. CPNA monomers with Boc and trityl groups on the N, S-termini. 
 
 Scheme 6: Two different routes toward the trityl and Boc protected sub-monomer. 
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With the monomers prepared above, we have tried solution based and also solid phase coupling 
of monomers to get dimers and oligomers. The studies towards synthesis of the oligomers are 
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discussed in chapter four. After analyzing the data from those studies, we concluded that utilizing 
the acetonide as the co-protecting group of N, S-termini in the continuous solid phase synthesis 
sequence is not feasible. Therefore, we decided to use different protecting groups which can be 
deprotected in milder conditions before the solid phase synthesis. Consequently, the new 
protocols had to be developed. 
After examining thoroughly, the trityl group was selected to be the protecting group for 
the thiol. Summarized in the Scheme 6 is the protocol to prepare the trityl protected monomers. 
The commercially available 34 was used to give 38a by the protocol we previously used. On the 
other hand, we have developed another protocol which utilizes the borane reduction. The reason 
why we have sought the other route for the same sub-monomer was not only did we want to 
improve the overall yield but also we wanted to prepare the optically pure monomers. Like 
peptides, PNAs oligomers also require optically pure monomers since they usually need to have 
certain lengths for their sequence specific activity. So, the newly developed route begins with an 
amide formation of 34 with glycine methyl ester to give 37 which is then subjected to the key step, 
the borane reduction. The mild borane reduction is reportedly very likely to cause the 
epimerization of the alpha stereogenic center.87 After the reduction, we were able to isolate the 
desired 38b. However, along with 38, significant amounts of byproducts were observed. The 
major byproduct was identified as the alcohol compound which is the result of the reduction of the 
ester group. After numerous attempts, the best yield we obtained was 40 %. When we recover 
the starting material, the yield improves slightly to 55 %. Nevertheless, it is still important to make 
sure which route gives less epimerization. Theoretically, we know that the reductive amination 
route has to go through the aldehyde stage so it is very difficult to avoid the epimerization with the 
protocol using reductive amination. To prove this matter experimentally, we first coupled both 38a 
and 38b with an optically pure Fmoc-proline to perform an NMR analysis of the ratio of potential 
diastereomers. Although this NMR study convincingly showed the difference of the spectra 
formed by the two different routes, yet we were not able to quantitatively analyze the data. 
Thereafter, we have decided to use HPLC with a chiral column. After finding good resolution 
conditions for the racemic 38, both 38a and 38b were tested and it turned out to give the result 
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that we were anticipating. The reductive amination route which had been conducted with extreme 
care to avoid the epimerization gave about 10% of the minor diastereomer while the other route 
gave no epimerization at all. The ee (enantiomeric excess) values for 38a and 38b were 80 % 
and 99.9% respectively. This result technically was exceedingly important for us because the 
purity of the single unit for oligomers is critical. For example, if one wants to make a peptide or an 
oligomer with the 10 units in the sequence, and if the optical purity of the single unit used is only 
90%, one could get the desired product with the maximum yield of 60% with a possible 1022 
diastereomers and the other enantiomer. As the oligomer gets longer, the efficiency drops 
precipitously. Therefore, although the second step has a productivity issue, the borane route still 
is valuable. 
 
Scheme 7: Preparing the N-Boc, S-trityl Monomers. 
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 The optically pure 38b was then coupled with the four different nucleo bases. As shown 
in Scheme 7, all four reactions under the same conditions gave the desired 39, 40, 41 and 42 
with quantitative yields. 
 
2.5. Synthesis of CPNA monomers with the alkyl groups on the S-terminus. 
 
 After the preliminary study on the solid phase synthesis, which is discussed in chapter 
four, we’ve learned that it is better to reduce the numbers of steps in the solid phase synthesis if it 
is possible. Therefore, we decided to introduce the side chains that we designed before the solid 
phase synthesis. As a sequence, our protocol again had to be totally revised. 
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Figure 19: Possible pathways for CPNA backbones. 
   
 To come up with a new protocol, we needed to carefully look at all the termini and their 
possible protecting groups in the big picture. We decided to use Fmoc group for N-terminus 
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because it is a good function that can be utilized in the solid phase synthesis when one needs to 
quantitatively analyze the coupling. Matters regarded with the solid phase synthesis will be 
discussed in detail in chapter four. After fixing the N-terminus protecting group as Fmoc group, 
the C-terminus should have an orthogonal protection. Therefore, the acid labile tert-butyl ester 
was selected as the protecting group. The remaining S-terminus must have a protecting group 
which can be cleaved selectively from both of the other termini. After considering it thoroughly, we 
chose the trityl group. With all the protective groups set, we had to go over all the possible ways 
to carry out our synthesis. 
 Illustrated in Figure 19 are the possible pathways including the new protocol to get the 
Fmoc protected backbone of our CPNA monomers. Route A is one of the most conventional 
ways to construct the PNA backbone. However, we now have learned that this route can cause 
epimerization. Route B proved to have no epimerization, but this route also has a problem which 
is the poor yield of the key step, borane reduction. So, we had to look for the alternatives. Route 
C, elaborated in Scheme 8, is a procedure that is designed to use a SN2 reaction to couple  
 
Scheme 8: A SN2 protocol (Route C). 
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Scheme 9: Preparation of the charged alkyl bromides for S-alkylation. 
 
H2N NH2 CbzHN NHBoc
CbzHN N
H
O
Br
CbzHN NH2
(46) 48
49
50
(a) (Boc)2O, CHCl3, 0 oC. (b) Cbz-Cl, THF, 0 oC. 
(c) TFA, DCM (d) bromoacetyl bromide, Na2CO3,DCM, -10 oC 
(e) 1,3-bis(benzyloxycarbonyl) -2-methyl -2-pseudothiourea,  HgCl2, TEA, DCM, rt, 3 hr
H2N NHBoc
47
N
H
NHBocCbzHN
NCbz
N
H
NH2CbzHN
NCbz
N
H
N
H
CbzHN
NCbz
5152
53
a b
c
d
e
c
d
(R1Br)(R2Br)
O
Br
by Laura Anderson by Mellisa Topper
 
 
our cysteine and the glycine ester. A mild borane reduction of 43 gave 44 with a good yield and 
the bromo compound 45 was obtained when 44 was treated with the phosphorus tribromide in 
CCl4. The next step was the SN2 reaction that would complete the backbone, but all the 
conditions we tried gave no desired product or Fmoc-deprotected by-product. As an alternative to 
route C, a totally new procedure was proposed. The protocol was examined to be promising both 
in terms of productivity and optical purity. Using this procedure shown in Scheme 10, the charged 
alkyl chains are successfully induced on to the S-termini. Two different alkyl chains were initially 
designed and synthesized by the sequences that were conducted by Melissa Topper and Laura 
Anderson.  
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Scheme 10: Preparation of R1-alkylated Fmoc Monomers. 
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 The procedure to synthesize the R1-attached Fmoc monomers begins with the 
commercially available 43. The simple amide formation using DCC in the presence of HOBt was 
well precedented88 and gave us 54 with 92% yield. The borane reduction which is also used for 
route B earlier gave us the reduced amine 55 with 65 % yield. This time, because the substrate 
for the borane reduction didn’t have any other borane labile functional group, the yield of the 
reduction was improved. The next step was the key step to couple 55 and the bromo acetate in 
the presence of a bulky amine base. The SN2 reaction gave 56 with 92% yield. Trityl protected 56 
then had to be deprotected selectively. 15% TFA solution in DCM was able to cleave the trityl 
group from the thiol without deprotecting the tert-butyl ester. 
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Scheme 11: Preparation of R2-alkylated Fmoc Monomers. 
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Trityl cation was quenched by triethylsilane89 and the progress of the reaction can be monitored 
by the color of the solution because the trityl cation in the solution displays a distinctive yellow 
color. The naked thiol compound was then directly subjected to the next step without further 
purification.  
 
Scheme 12: Preparation of S-methyl Fmoc Monomers. 
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The alkylation of the crude thiol with 50 in the presence of the sodium hydroxide in EtOH yielded 
the sub-monomer 57 with a 90% yield for the 2 step sequence. 57 was then coupled with acetic 
  44
acid derivatives of the nucleo bases using the HATU protocol to give monomers 58, 59, 60 and 
61 with a quantitative yields. With the protocol developed in Scheme 10, R2-alkylated Fmoc 
monomers are also prepared as shown in Scheme 11. 
To control the degree of charge on the CPNA oligomer, we needed to have a neutral backbone 
as well. Therefore, a neutral alkyl chain had to be designed or selected. The simple methyl group 
was chosen as the neutral alkyl group due to its availability and the simplicity. The procedure to 
synthesize the neutral monomers with all the bases is summarized in Scheme 12 and the 
protocol is quite similar to that of charged monomers. 
 
Scheme 13: Alkylated Boc monomers with R1 and methyl groups.  
BocHN CO2H
S
Ph
Ph Ph
BocHN
S
Ph
Ph Ph
NH2BocHN CONH2
S
Ph
Ph Ph
DCC, HOBT, 
NH4OH
THF
BH3.THF
THF
98%
THF
Methyl bromoacetate, 
 DIPEA, DMAP(Cat.)
BocHN
S
Ph
Ph Ph
N
H
CO2Me
BocHN
RS
N
H
CO2Me
92%
i)TFA/DCM, Et3SiH
ii) NaOH, R1Br, MeOH, TBAI
    87 %
or MeI, NaOH, MeOH, 91%
BocHN
RS
N CO2Me
O
(Base)
70 %
13, 14, 29 or 33
  HATU, TEA
DMF
34
72 73
38c
74 R = Me
75 R = R1 76  R= Me and T   77  R= Me and G78  R= Me and C   79  R= Me and A
80  R= R1  and T   81  R= R1  and G
82  R= R1  and C   83  R= R1  and A
96~99 %
 
 
Many of reported PNA oligomers were synthesized with Boc-solid phase synthesis. As 
summarized in Scheme 13. We have also prepared our alkylated CPNA monomers with Boc 
protecting group. The protocol adopted the procedure that was developed for alkylated Fmoc 
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CPNA monomers. Overall, the yields for the Boc-protocol were slightly better than the Fmoc 
protocol. 
 
2.6. Inversed CPNA: new CPNA backbone. 
 
H2N N
OHS O
B
OH
C-terminus
N-terminus
S-terminus
Unit of CPNA
N
HS
NH2
O
HO
O
B
Unit of inversed CPNA
C-terminus N-terminus
S-terminus
 
Figure 20: Comparison of the CPNA and Inversed CPNA (I-CPNA). 
 
 A totally different cysteine based PNA backbone was designed when we were developing 
the protocols for CPNA monomers. As it can be seen in Figure 20, this new backbone is simply 
an inverted version of the CPNA backbone. C and N termini of the new backbone are located on 
the other side of the backbone as compared to the normal CPNA. Moreover, the nucleo bases 
are connected to the nitrogen which comes from the original cysteine while in the normal CPNA, 
the nitrogen from the cysteine becomes the N-terminus. We believe this design can probably help 
the solid phase synthesis of its oligomers because the N-terminus of this new monomer is a 
primary amine with less steric hindrance for coupling to make the amide bond that connects the 
monomer units. The steric nature of the monomers can well be crucial factor for their coupling 
efficiency. On the other hand, coupling of the nucleo base derivatives could be tougher since the 
secondary amine is sterically hindered as compared to that of the normal CPNA. The protocol to 
synthesize the inversed-CPNA monomer is shown in Scheme 14.  This protocol shares the same 
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starting materials with normal CPNA monomers that are shown in Scheme 13. When the 
synthesis reached to 73, the procedure becomes different. The primary amine, 73 gets protected 
with the Fmoc group to give 84 with a good yield. The Fmoc protected amine is now the N-
terminus for the monomer. So it does not get deprotected until it reaches the solid phase 
synthesis stage. The other Boc protected amine on 84 however, needs to be deprotected as well 
as the S-terminus that is protected with the trityl group. Since both Boc and trityl groups are acid 
labile group, we needed to be careful when we conduct the selective deprotection of 84. After 
trying a couple of preliminary experiments, it was figured that the both N and S termini can be 
selectively deprotected. 
 
Scheme 14: synthesis of inversed-CPNA monomer. 
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S
NHFmoct-BuO2C
O
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To selectively deprotect the thiol of 84, we can treat 10 % TFA solution in DCM at room 
temperature in the presence of the triethylsilane as a scavenger of the trityl cation. For selective 
Boc deprotecton, simply stirring it in the 50% TFA solution in DCM for about an hour and 
concentration of the reaction solution would give the TFA salt of the deprotected amine. By the 
way, we deprotected the thiol selectively and put the alkyl group to get 85 with 87% yield for 2 
steps. Then the Boc group was deprotected with the HCl gas instead of TFA solution because the 
HCl salt of the amine gave the better yield for the next alkylation step. So, the crude HCl salt from 
the 85 was subjected to the alkylation with the bromo t-butyl acetate in the presence of DIPEA in 
DMF. The overall yield for the two steps to get 86 was 60%. The subsequent step was to couple 
the nucleo base derivatives on 86.  Surprisingly, the condition that gave us always good yield for 
nucleo base coupling didn’t work for this substrate. DCC and EDC based coupling conditions and 
other coupling conditions didn’t work for 86 either. Luckily, when we treated the acid chloride 
version of the nucleo base, it gave us the desired product 87 with about 50% yield and we were 
able to recover most of the starting material unreacted. The thymine acetic acid chloride was 
freshly generated before the coupling by refluxing 13 with thionyl chloride.  
 
2.7. Conclusion. 
 
Various versions of CPNA monomers have been synthesized. Both Boc and Fmoc protected 
protocols have been developed to provide the wider options for the solid phase synthesis. 
Notably, the unique protocols that utilize the borane reduction are free of epimerization. This 
astonishing result can contribute to other PNA projects or peptide chemistry. As reported in the 
latter part of this chapter, the inverse-CPNA protocol has also revealed a unique synthetic 
strategy and it may have a structural advantage for solid phase synthesis. In short, demonstrated 
throughout this chapter are synthetic strategies that successfully synthesized monomers of the 
CPNA with the charged alkyl chains which could enhance the water-solubility and cell 
permeability of the CPNA oligomers.  
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3. Chapter Three: Experimental Procedures for Chapter Two. 
3.1. Introduction. 
 
All the experiments were carried out under argon or nitrogen atmosphere using oven 
dried glassware. Most of chemicals were purchased from Aldrich Chemical Co. and Acros 
Organics. When the solvents must be anhydrous, CH2Cl2, THF and diethyl ether were distilled 
over calcium hydride or proper metals. 1H(250 MHz) and 13C(62.5 MHz) nuclear magnetic 
resonance (NMR) data were recorded at room temperature in CDCl3 using a Bruker DPX 250 
spectrometer unless otherwise noted. High Resolution Mass Spectrometry (HRMS) spectra were 
recorded using an Agilent 1100 Series in the ESI-TOF mode. Selected NMR and Mass spectra 
are available in the Appendix section. 
 
 
3.2. Experimental procedures for compounds in Schemes 2 and 3. 
3.2.1. Preparation of 1. 
 
L-cysteine HCl
S
H
N OH
O
HCl
1
reflux
acetone
 
L-Cysteine HCl monohydrate (20 g) was refluxed in 1 L of acetone for 3 hr and allowed to cool to 
RT.  The resulting white solid was filtered and washed with ice-cold acetone twice and dried 
under vacuum to yield 23 g of 1 as a white solid in a 92% yield.   
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3.2.2. Preparation of 2. 
 
 
S
H
N OH
O
HCl
S
N OH
OBoc
1 2
(Boc)2O, DIEA
Acetonitrile
 
1 (10 g) was suspended into 200 mL of anhydrous acetonitrile and 15.5 g (1.4 eq) of (Boc)2O and 
8.8 mL (1.05 eq) of DIPEA was added to make a solution and the mixture was stirred at RT for 3 
days.  The solvent was evaporated under vacuum and the residue was taken up in diethyl ether.  
The white precipitate was removed by filtration through Celite™ and the filtrate was washed with 
0.1 N HCl twice and once with water and brine.  The organic layer was concentrated to an oil 
(sometimes solid) and crystallized (or recrystallized) from hexanes to give 5 g of 2 as a white 
solid in a 40% yield.   
 
3.2.3. Preparation of 3. 
 
S
N OH
OBoc
S
N N
OBoc
O
2 3
ETOAc
N,O-dimethylhydroxylamine,
DCC, TEA
 
2 (3.8 g) was dissolved in 100 mL of EtOAc and 3.2 g (1.1 eq) of DCC, 1.52 g (1.1 eq) of N,O-
dimethylhydroxylamine HCl, and 1.55 mL of DIPEA were added into the solution.  After stirring at 
rt for 4 hours, the solution was concentrated and subjected to flash column chromatography 
which yielded 3 g of 3 as a white solid in a 70% yield.  (Rf = 0.55, Hexane/EtOAc = 1/1)  
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3.2.4. Preparation of 4. 
 
S
N N
OBoc
O
S
N H
OBoc
3 4
DIBAL-H
Et2O
 
3 (2.0 g) was dissolved in 100 mL of diethyl ether and cooled to 0 ˚C and 10 mL of 1M  DIBAL-H 
solution in hexanes (1.5 eq) was slowly added.  The mixture was stirred for 3 hr at 0 ˚C and then 
carefully quenched with methanol.  After stirring for 30 min, the aluminum complex was filtered 
through the Celite™ and washed with EtOAc. The organic filtrate was concentrated to give 1.45 g 
of 4 as a white solid in a 92% yield.  
 
3.2.5. Preparation of 5. 
 
S
N H
OBoc
4 S
N NH
Boc
CO2Me
5
ClH.H2N CO2Me, MgSO4,
NMM, NaBH3CN  
4 (1.11 g) was dissolved in 100 mL of anhydrous THF and 3 g of MgSO4, 570 mg (1  eq) of 
glycine methyl ester HCl, and 500 mL (1.05 eq) of N-methylmorpholine were added.  After stirring 
for 10 min, 600 mg (2 eq) of NaBH3CN was added and the mixture was stirred for 4 hr.  The 
concentrated mixture was subjected to the flash column chromatography to give 1 g of 5 as a 
white solid in a 75% yield. (Rf = 0.39, Hexane/EtOAc = 1/1) 
 
3.2.6. Preparation of 6. 
 
L-Cysteine methyl ester.HClL-Cysteine.HCl
6
MeOH
SOCl2, Reflux
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6) L-cysteine HCl monohydrate (30 g) was dissolved in 300 mL of methanol and the solution was 
cooled to 0 ˚C.  14.5 mL (1.05 eq) of thionyl chloride was carefully added dropwise and the 
mixture was refluxed for 3 hr. After concentration of the solution, the white solid residue was 
recrystallized with MeOH and EtOAc to yield 30 g of 6 in a 95% yield.   
 
3.2.7. Preparation of 7. 
 
L-Cysteine methyl ester.HCl
H
N
S
CO2Me
6
7
TEA,
Acetone, reflux
 
6 (5.0 g) was dissolved in 100 mL of acetone and 3.09 g (1.05 eq) of TEA was added. The 
solution was refluxed under Argon for 12 hr and the solution was concentrated and subjected to 
the column chromatography to give 4.1 g of 7 in an 85% yield. (Rf = 0. 33, Hexane/EtOAc = 1/1)  
 
3.2.8. Preparation of 8. 
 
H
N
S
CO2Me
7
N
S
CO2Me
Fmoc
8
Fmoc-Cl, NaHCO3
DCM
 
7 (1.0 g) was dissolved in 60 mL of DCM and 1.5 g of Fmoc-Cl and 3 g of NaHCO3 was 
suspended in the solution.  The mixture was vigorously stirred for 3 hr and the filtrate was 
concentrated.   Flash column chromatography gave 1.8 g of 8 in an 83% yield. (Rf = 0.45, 
Hexane/EtOAc = 2/1 ) 
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3.2.9. Preparation of 9. 
 
N
S
Fmoc
OH
9
N
S
CO2Me
Fmoc
8
DIBAL-H
THF
 
8 (1.37 g) was dissolved in 60 mL of anhydrous THF and the solution was cooled to 0 ˚C and 17 
mL of 1 M  DIBAL-H solution in hexanes was added under Argon.  The solution was stirred at 0 
˚C for 3 hr and quenched carefully with methanol.  After 30 min of stirring, the aluminum complex 
was filtered and washed with EtOAc thoroughly.  The combined organic layer was concentrated 
and subjected to flash column chromatography to yield 1.15 g of 9 in a 91% yield. (Rf = 0.31, 
Hexane/EtOAc = 2/1) 
 
3.2.10. Preparation of 10. 
 
N
S
CHO
Fmoc
10
N
S
Fmoc
OH
9
DCM
Dess-Martin Periodinane
 
9 (400 mg) was dissolved in 20 mL of anhydrous DCM and the solution was cooled to 0 ˚C.  
Dess-Martin Periodinane (2.3 mL, 15% in DCM) was added and stirred for an hr.  As soon as 
TLC detects the full conversion of the starting material, the reaction was quenched with saturated 
NaHCO3 solution and 10% sodium bisulfate solution.  The organic later was washed with brine, 
dried over sodium sulfate, concentrated, and subjected to the next step without further purification. 
(Rf = 0.6, Hexane/EtOAc = 2/1) 
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3.2.11. Preparation of 11. 
 
N
S
CHO
Fmoc
10
N
S
Fmoc
N
H
CO2Me
11
Glycine methyl ester Hydrochloride, TEA,
   MgSO4, NaBH3CN
THF
 
10 (700 mg) was dissolved in THF and 1.5 g of MgSO4 was suspended.  Glycine methyl ester 
(240 mg, 1 eq) and 202 mg (1.05 eq) of NMM were added with vigorous stirring.  After 10 min, 
250 mg of NaBH3CN was added and stirred for 4 hr.  The mixture was filtered and the filtrate was 
concentrated and subjected to flash column chromatography to yield 660 mg of 11 in an 80% 
yield. (Rf = 0.38, Hexane/EtOAc = 1/1) 
 
3.2.12. Preparation of 12. 
 
N
S
CHO
Fmoc
10
N
S
Fmoc
N
H
CO2tBu
12
glycine t-butyl ester. acetic acid, TEA,
   MgSO4, NaBH3CN
THF
 
The same reaction conditions with glycine t-butyl ester acetic acid (11) salt gave 12 in a 75% 
yield.   
 
  55
3.3. Experimental procedures for compounds in Schemes 3, 4 and 5. 
3.3.1. Preparation of 17. 
 
N
NN
N
H NH2
Cl
N
NN
N NH2
Cl
O
O
17
K2CO3, benzyl bromoacetate
DMF
 
2-Amino-6-chloro-purine (2.0 g) and 3.26 g K2CO3 were placed in 50 mL of DMF and the mixture 
was stirred for 1 hr and then 2.1 mL of benzyl bromoacetate was added in one portion.  The 
reaction mixture was stirred for 2 hr at room temperature and 2.5 gm of Celite™ was added and 
the mixture was filtered.  The Celite™ was washed with 2 mL of DMF.  The solution was 
concentrated to a volume of 80 mL and after cooling to 15 ˚C the mixture was filtered and the 
filtrate was evaporated to dryness. The residue was added to a mixture of ethyl acetate and water 
(20 mL/4 mL), and stirred for 10 min.  The crude product was collected upon filtration, washed 
with cold ethanol and dried overnight in high vacuum to give 2.5 g of 17 in a 70% yield.   
 
3.3.2. Preparation of 14. 
 
N
NN
N
O
NH2
HO
O
14
N
NN
N NH2
Cl
O
O
17
Na, Benzyl alcohol
 
Fresh cut pieces of sodium (304 mg) were added to 30 mL of benzyl alcohol.  The reaction was 
left for 1 hr at rt until the sodium was completely reacted.  17 (1.5 g) was added in one portion 
and the mixture was stirred overnight.  After addition of water (30 mL) and washing with diethyl 
ether, the pH was adjusted to 2 using 2 M NaHSO4.  The white solid was collected and dissolved 
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in 120 mL of ethanol:water (3:1).  14 (1.1 g) was obtained after cooling and filtration in an 80% 
yield.   
 
3.3.3. Preparation of 18. 
 
N
NN
N
H
NH2
N
NN
N
NH2
O
O
18
Ethyl bromoacetate, NaH
DMF
 
Adenine (5 g) was suspended in 75 mL of DMF.  NaH (1.6 g, 60% suspension) was added in 
portions over 1 hr at 10 ˚C with stirring.  The mixture was stirred at RT for 1 hr. ethyl 
bromoacetate (12.3 g) was added dropwise over 3 hr. The mixture was stirred at RT for 20 hr.  
The solution was evaporated to dryness in vacuo and stirred for 2 hr with 50 mL of water. 18 (4.5 
g, 55% yield) was collected by filtration, washed with water, and absolute ethanol. 
 
3.3.4. Preparation of 15. 
 
N
NN
N
NH2
O
HO 15
N
NN
N
NH2
O
O
18
NaOH
H2O
 
18 (3.75 g) was dissolved in 160 mL of water, followed by dropwise addition of 50 mL of 2 M 
NaOH solution at 0 ˚C.  After 30 min, the temperature was allowed to reach RT and the reaction 
mixture was stirred for 1 hr the pH was adjusted to 2.5 with 2 M NaHSO4. 15 (2.75 g), a gray solid, 
was obtained after filtration and washing with cold water for an 84% yield.  
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3.3.5. Preparation of 19. 
 
HN N
O
NH2
N N
O
NH2O
O
19
KOt-Bu,
 benzyl bromoacetate
DMF
 
To 2.06 g of cytosine in 18 mL of DMF was added 2.32 g of potassium tert-butoxide and the 
mixture was heated to 100 ˚C for 2 hr. The reaction was cooled to 10 ˚C and 3.21 g of benzyl 
bromoacetate was added dropwise over 30 min. The reaction was allowed to warm to RT while 
stirring for 12 hr and quenched with 1.2 mL of acetic acid, concentrated in vacuum.  The residue 
was re-suspended in 20 mL of water and stirred for 4 hr and filtered, washed with water, and 
dried under high vacuum to recover 3.8 g of a pinkish powder, 19, in an 85% yield.   
 
3.3.6. Preparation of 16. 
 
N N
O
NH2
HO
O
16
NaOH
H2O
N N
O
NH2O
O
19  
The same procedure as with 15 was applied to give 2.5 g of compound 16 from 4 g of 19 in a 
90% yield. 
 
3.3.7. Preparation of 20. 
 
S
N N
H
Boc
CO2Me
5
S
N N
Boc
CO2Me
O
(T) 20
13, HATU, TEA
DMF
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To a solution of 23 mg of 5, 13 mg of 13, 28 mg of HATU in 0.5 ml of DMF was added 8 mg of 
TEA and the reaction mixture was stirred overnight.  The solution was concentrated in vacuo and 
the residue was diluted with EtOAc, washed with brine, dried over the sodium sulfate, 
concentrated, and subjected to column chromatography to yield 30 mg of compound 20 in an 
86% yield.  (Rf = 0.55, EtOAc) 
 
3.3.8. Preparation of 21, 24 and 25. 
 
S
N N
Boc
CO2Me
O
(G) 21
N
S
Fmoc
N CO2Me
O
(T) 24
N
S
Fmoc
N CO2tBu
O
(T) 25
N
S
Fmoc
N
H
CO2Me
N
S
Fmoc
N
H
CO2tBu
11
12
S
N N
H
Boc
CO2Me
5
13, HATU, TEA
DMF
13, HATU, TEA
DMF
14, HATU, TEA
DMF
 
The same procedure as with 20 was applied to give 21 in an 80 %, 24 in a 93%, and 25 in a 70% 
yield with the respective protecting groups. (Rf = 0.4, 0.6, 0.65, EtOAc) 
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3.3.9. Preparation of 35. 
 
BocHN CO2H
S
Ph
Ph Ph
BocHN
S
N
OMe
Ph
Ph Ph
O
Me93%
a
34 35  
Solution of 34(2 g), EDC.HCl(910 mg), DMAP(630 mg) and N,O-dimethyl hydroxylamine HCl(463 
mg) in  DCM(20 ml) was stirred for 4hr. Reaction mixture was washed with water and brine, 
concentrated, and the crude product was subjected to a flash column chromatograph to give 2 g 
of white soild 35 in a 93% yield.  (Rf = 0.55, EtOAc/Hexane = 1/1). 
 
3.3.10. Preparation of 36. 
 
BocHN
S
N
OMe
Ph
Ph Ph
O
Me
BocHN
S
Ph
Ph Ph
O
H
35 36
DIBAL-H, Et2O, 0 oC, 3hr
 
35 (410 mg) was dissolved in 10 mL of diethyl ether and cooled to 0 ˚C and 1.05 mL of 1M 
DIBAL-H solution in hexanes (1.3 eq) was slowly added.  The mixture was stirred for 3 hr at 0 ˚C 
and then carefully quenched with methanol.  After stirring for 30 min, the aluminum complex was 
filtered through the Celite™ and washed with EtOAc. The organic filtrate was concentrated to 
give 370 mg of oily product 36. The crude product was subjected directly to the next reductive 
amination step without further purification. 
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3.4. Experimental procedures for compounds in Schemes 6 and 7. 
3.4.1. Preparation of 37. 
 
BocHN CO2H
S
Ph
Ph Ph
34
Glycine methyl ester.HCl
EDC.HCl, DMAP, DCM
 rt 4hr
BocHN
S
N
H
CO2Me
Ph
Ph Ph
O
37  
Solution of 2 g of 34, 910 mg of EDC· HCl, 630 mg of DMAP and 600 mg of Glycine methyl 
ester·HCl in 20 mL of DCM was stirred for 4 hrs. Reaction mixture was washed with water and 
brine, concentrated, and the crude product was subjected to a flash column chromatograph to 
give 2.1 g of white soild 37 in a 92% yield.  (Rf = 0.55, EA/Hexane = 1/1). 
 
3.4.2. Preparation of 38a. 
 
BocHN
S
N
H
CO2Me
Ph
Ph Ph 38a
BocHN
S
Ph
Ph Ph
O
H
36
Glycine methyl ester.HCl, 
MgSO4,  NMM, NaBH3CN
THF, rt, 6hr
 
Crude 36 (260 mg) was dissolved in anhydrous THF (10 mL) and MgSO4 (450 mg), glycine 
methyl ester·HCl (73 mg), and N-methylmopholine (67 mL) were added.  After stirring for 5 min at 
room temperature, NaBH3CN (75 mg) was added and the mixture was stirred for 8 hr.  The 
concentrated mixture was subjected to the flash column chromatography to give 177 mg of 38a 
as a white solid in a 60% yield (2 steps). ( Rf = 0.4, Hexane/EtOAc = 1/1) 
 
3.4.3. Preparation of 38b. 
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BH3.THF, THF, reflux, 20hr
BocHN
S
N
H
CO2Me
Ph
Ph Ph
O
37
BocHN
S
N
H
CO2Me
Ph
Ph Ph 38b  
To the solution of 37 (500 mg) dissolved in anhydrous THF (10 mL) in a flame dried 25 mL round 
bottom flask was slowly added 1 M BH3·THF (2 mL) solution at room temperature. The reaction 
mixture was refluxed for 20 hrs and then treated with  morpholine (0.5 mL). The reaction mixture 
was stirred for 2 hrs. Reaction mixture was diluted with EtOAc and filtered through Celite™. The 
filtrate was concentrated and subjected to a flash chromatography to give 38b (150 mg) in a 40% 
(55 % after recovering 130 mg of starting material).  
 
3.4.4. Preparation of 39. 
 
BocHN
S
N CO2Me
Ph
Ph Ph
O
N
HN
O
O
BocHN
S
N
H
CO2Me
Ph
Ph Ph 38b
>95%
HATU, 13, TEA, DMF
 rt, 2hr
39
 
To a solution of 15 mg of 38b, 10 mg of 13, 20 mg of HATU in 0.3 mL of DMF was added 5 mg of 
TEA and the reaction mixture was stirred for 15 hr.  The solution was concentrated in vacuo and 
the residue was diluted with EtOAc, washed with brine, dried over the sodium sulfate, 
concentrated, and subjected to column chromatography to yield 19.5 mg of 39 in a 99% yield.  (Rf 
= 0.5, EtOAc) 
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3.4.5. Preparation of 40, 41 and 42. 
 
BocHN
S
N CO2Me
Ph
Ph Ph
O
N
BocHN
S
N
H
CO2Me
Ph
Ph Ph 38b
40
N N
N NH2
BnO
BocHN
S
N CO2Me
Ph
Ph Ph
O
BocHN
S
N
H
CO2Me
Ph
Ph Ph 38b
BocHN
S
N CO2Me
Ph
Ph Ph
O
BocHN
S
N
H
CO2Me
Ph
Ph Ph 38b
N
N
N
O
NHCbz
N
N
N
CbzHN
41
42
>95%
HATU, 14, TEA, DMF
 rt, 2hr
>95%
HATU, 43, TEA, DMF
 rt, 2hr
>95%
HATU, 47, TEA, DMF
 rt, 2hr
 
The same procedure as with 61 was applied to give, 62, 63 and 64 from 55b in 95~99% yield for 
each compound. 
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3.5. Experimental procedures for compounds in Schemes 8, 9, 10, 11, 12 and 13. 
3.5.1. Preparation of 47. 
 
(Boc)2O, CHCl3, 0 oC
H2N NH2
(46)
H2N NHBoc
47
 
To 1,3-propanediamine (150 mL, 1.8 mol) in CHCl3 (300 mL) at 0 ºC was added (Boc)2O (6.42 g, 
32 mmol) dissolved in CHCl3 (40 mL) dropwise during 0.5 hr.  The reaction mixture was allowed 
to warm to ambient temperature and stirred for 3 hr.  After filtering the mixture, the filtrate was 
concentrated in vacuo and the oily residue was dissolved in EtOAc (150 mL).  The solution was 
washed with brine and dried over Na2SO4.  Evaporation of the solvent in vacuo gave 47 (4.92 g) 
as a clear oil.  Yield 89%. 
 
3.5.2. Preparation of 48. 
 
CbzHN NHBoc
48
H2N NHBoc
47
Cbz-Cl, THF, 0 0C
 
To a solution of 47 (4.92 g, 28.3 mmol) in THF (150 mL) at 0 ºC was added benzyl chloroformate 
(5.23 mL, 37 mmol) in NaOH (3 N, 30 mL).  The reaction mixture was allowed to warm to ambient 
temperature and stirred for 3 hr.  The solution was acidified with HCl (6 N), extracted with EtOAc.  
The organic layer was dried over Na2SO4, concentrated in vacuo to give the crude product which 
was flash chromatographed on silica gel (EtOAc/Hexane, 1:1) to provide 48 (7.47 g, 24 mmol) as 
a clear oil.  Yield 86% 
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3.5.3. Preparation of 49. 
 
CbzHN NH2
49
CbzHN NHBoc
48
TFA, DCM
 
A solution of 48 (4.53 g, 15 mmol) in DCM (10 mL) was added TFA (10 mL).  The reaction was 
stirred at room temperature for 0.5 hr.  The solvents were removed in vacuo.  To the yellow, oily 
residue, DCM (15 mL) was added and removed in vacuo.  This step was repeated four more 
times.  The solvent was removed in vacuo to give the crude product which was flash 
chromatographed on silica gel (DCM/MeOH, 4:1) to provide 49 (4.62 g, 14 mmol). Yield 96%. 
 
3.5.4. Preparation of 50. 
 
CbzHN N
H
O
Br
50
CbzHN NH2
49
Bromoacetyl bromide,
Na2CO3, DCM, -10 oC
 
To compound 49 (4g, 12.3 mmol),40 mL of DCM and 20 mL of saturated aqueous Na2CO3 were 
added.  The mixture was vigorously stirred with a mechanical stirrer and cooled to -10 ºC before 
the addition of bromoacetyl bromide  (2.49 gm, 12.3 mmol).  Stirring was continued for 30 min at 
0 ºC. The reaction mixture was warmed to ambient temperature and then stirred overnight. After 
18h, the solvents were removed in vacuo.  To the resulting residue, EtOAc (150 mL) and water 
(100 mL) were added.  The two phases were separated and the organic layer was washed with 
5% NaHCO3 (100 mL), 15 % citric acid solution (100 mL), and brine (3 x 100 mL).  Drying over 
Na2SO4 and removal of the solvent under reduced pressure afforded the crude product as a white 
solid.  Purification by flash chromatography (EtOAc/hexane 1:1) gave 50 as a white solid      (3.6 
g, 1.09 mmol). Yield 89% 
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3.5.5. Preparation of 51. 
 
H2N NHBoc
47
N
H
NHBocCbzHN
NCbz
51
1,3-bis(benzyloxycarbonyl) 
-2-methyl -2-pseudothiourea
HgCl2, TEA, DCM, rt, 3h
 
Compound 47 (2.6 g, 14.92 mmol) was dissolved in anhydrous DCM and 7.15 mL of triethylamine 
was added.  HgCl2 (6.07 g, 22.38 mmol) was added to this mixture followed by the portioned 
addition of 1,3-bis(benzyloxycarbonyl)-2-methyl-2-pseudothiourea, (6.15 g, 17.2 mmol).  The flask 
flushed with Ar and reaction was stirred at room temperature for 3 hours. After reaction was 
completed (3 hr), the mixture was filtered through Celite™ under vacuum and the residue was 
washed with methanol. The filtrate was then concentrated under reduced pressure and the crude 
was purified by column chromatography (1:1 EtOAc/hexane) to give 6.5 g of 51 as a pale, thick oil 
in a 90% yield. 
 
3.5.6. Preparation of 52. 
 
N
H
NHBocCbzHN
NCbz
51
N
H
NH2CbzHN
NCbz
52
TFA, DCM
 
Compound 51 was dissolved in a 1:1 mixture of DCM  and Trifluoroacetic acid.  After strring at 
room temparature for 1h,  the solvent was evaporated under reduced pressure and the crude 
compound 52 was obtained and was subjected to the next reaction without purification. For 
Analyzing purpose, crude compound was purified by column chromatography (89:10:1, DCM: 
MeOH: NH4OH). 
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3.5.7. Preparation of 53. 
 
N
H
NH2CbzHN
NCbz
52
N
H
N
H
CbzHN
NCbz
53
O
Br
Bromoacetyl bromide, Na2CO3
DCM, -10oC
 
Compound 52 as the trifluoroacetate salt (5.6 g) was dissolved in 40 mL of CH2Cl2 and 40 mL of 
sat. aqueous sodium carbonate.  This mixture was stirred and cooled to -10 °C.  Bromoacetyl 
bromide (0.8 mL) was added and stirring continued for 0.5 hr at 0 °C before a second portion of 2 
(0.4 mL) was added.  The reaction was left stirring for 3 hrs.  The reaction mixture was poured 
into 100 mL EtOAc and 80 mL of water.  The phases were separated and the organic layer was 
washed with 5% NaHCO3 (100 mL), 1 M HCl (100 mL), and brine (100 mL x 2).  Crude was dried 
over Na2SO4, concentrated under vacuo and subjected to column chromatography (6:4 = EtOAc: 
hexane) to give 1.65 g of 53 as white solid in a 55% yield for 2 steps.  
 
3.5.8. Preparation of 54. 
 
FmocHN CO2H
S
Ph
Ph Ph
FmocHN CONH2
S
Ph
Ph Ph
DCC, HOBT, 
NH4OH
THF43 54  
Synthesis of (R)-(9H-fluoren-9-yl)methyl 1-amino-1-oxo-3-(tritylthio)propan-2-ylcarbamate, 54. To 
a solution of 43 (2 g, 3.41 mmol), HOBT (549 mg, 4.1 mmol) and DCC (832 mg, 4.1 mmol) in 
THF (10 mL) was added 28% NH4OH (715 mL,  5.1 mmol) at 0 °C. After 2 hr of stirring at 0 °C, 
the reaction mixture was filtered through CeliteTM and filtrate was concentrated, diluted with 
EtOAc, and washed with water and brine. The organic layer was dried over sodium sulfate, 
concentrated and subjected to flash column chromatography to give 54 (1.85 g, 92%) as a white 
solid. 
 
  67
3.5.9. Preparation of 55. 
 
FmocHN
S
Ph
Ph Ph
NH2
FmocHN CONH2
S
Ph
Ph Ph
BH3.THF
THF54 55
 
Synthesis of (R)-(9H-fluoren-9-yl)methyl 1-amino-3-(tritylthio)propan-2-ylcarbamate, 55.    To 
solution of 54 (430 mg, 0.74 mmol) in THF (3 mL) was added 1 M Borane·THF complex (2.2 mL, 
2.2 mmol) at 0 °C and after stirring at 0 °C for 3 hr, the reaction mixture was heated to 70 °C and 
stirred for 12 hrs. The reaction mixture was cooled to 0 °C and quenched by MeOH, the reaction 
mixture was concentrated and diluted with MeOH and concentrated again in vacuo. The 
concentrated oil was subjected to flash column chromatograph to afford 55 (256 mg) in a 61% 
yield. 
 
3.5.10. Preparation of 56. 
 
FmocHN
S
Ph
Ph Ph
N
H
CO2t-BuFmocHN
S
Ph
Ph Ph
NH2 BrCH2CO2t-Bu, DIPEA
THF55 56  
Synthesis of 56.   To a solution of 55 (123 mg, 0.21 mmol) in THF (3 mL) was added tert-butyl 
bromoacetate (41.5 mg, 0.21 mmol) and DIPEA (0.040 mL, 0.23 mmol) at 0 °C. The reaction 
mixture was slowly allowed to warm to r.t. The reaction mixture was concentrated in vacuo, 
diluted with EtOAc and washed with brine. The organic layer was dried over sodium sulfate, 
concentrated in vacuo, and subjected to a flash column chromatography to give 56 (133.5 mg, 
90%).  
 
  68
3.5.11. Preparation of 57. 
 
FmocHN
S
N
H
CO2t-Bu
N
H
O
CbzHN
FmocHN
S
Ph
Ph Ph
N
H
CO2t-Bu i) TFA/DCM, Et3SiH
ii) R1Br, NaOH, EtOH56 57  
Synthesis of (R)-tert-butyl 13-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3,9-dioxo-1-phenyl-2-
oxa-11-thia-4,8,15-triazaheptadecan-17-oate, 57.    To a solution of 56 (50 mg, 0.086 mmol) and 
in DCM (5 mg) stirring at 0 °C was added TFA (2 mL). The reaction mixture was treated with 
triethylsilane (8.5 mg, 0.086 mmol). The reaction mixture was stirred for 30 min at 0 °C and 
concentrated in vacuo.  The crude product was dissolved in EtOH (2 mL) and the solution was 
cooled to 0 ˚C. Aqueous NaOH (0.2M, 0.8 mL) was added slowly to the solution followed by 
addition of the alkyl bromide, (25 mg). The reaction was stirred for 4 hrs at 0 °C. After the removal 
of organic solvents in vacuo, the residue was diluted with EtOAc and washed with water and 
brine. The organic layer was dried over sodium sulfate, concentrated in vacuo, and subjected to 
flash column chromatography to give 57 (46.3 mg, 92%).  
 
3.5.12. Preparation of 58. 
 
FmocHN
S
N CO2t-Bu
N
H
O
CbzHN
O
N
HN
O
O
FmocHN
S
N
H
CO2t-Bu
N
H
O
CbzHN
HATU, TEA, 
Thymine acetic acid
DMF
5857
 
General procedure for the nucleobase coupling : Synthesis of (R)-tert-butyl 13-(((9H-fluoren-
9-yl)methoxy)carbonylamino)-15-(2-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)acetyl)-3,9-
dioxo-1-phenyl-2-oxa-11-thia-4,8,15-triazaheptadecan-17-oate, 58.   To a stirring solution of 57 
(22 mg, 0.032 mmol), HATU (18 mg, 0.048 mmol) and Thymine acetic acid (9 mg, 0.048 mmol) in 
DMF was added TEA (5 mg) at r.t. for 4 hr. 
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The reaction mixture was diluted with EtOAc, washed with cold water and brine, dried over 
sodium sulfate, concentrated in vacuo and subjected to flash column chromatography to give 58 
(25.8 mg, 95%). 
3.5.13. Preparation of 67. 
 
FmocHN
MeS
N
H
CO2t-BuFmocHN
S
Ph
Ph Ph
N
H
CO2t-Bu i)TFA/DCM, Et3SiH
ii)MeI, NaOH, EtOH
57
67
 
Synthesis of 67. To a solution of 57 (1.12 gm, 1.6 mmol) in DCM (40 mL) stirring at 0 °C was 
added TFA (4 mL). The reaction mixture was then treated with triethylsilane (0.187 gm, 1.6 mmol). 
The reaction mixture was stirred for 30 min at 0 °C and concentrated in vacuo.  The crude 
product was kept on vacuum for 12 hours and dissolved in EtOH (75 mL). After cooling the 
solution to 0 °C, aqueous NaOH (2M, 2.42 mL) was added slowly, followed by addition of 
iodomethane, (1.0 mL). The reaction was stirred for 10 min at 0 °C. After the removal of organic 
solvents in vacuo, the residue was diluted with EtOAc and washed with water and brine. The 
organic layer was dried over sodium sulfate, concentrated in vacuo and subjected to flash column 
chromatography to give 67 (0.67 g, 90%).  
 
3.6. Experimental procedures for compounds in Schemes 14. 
3.6.1. Preparation of 72. 
 
CO2HBocHN
SPh
Ph
Ph
CONH2BocHN
SPh
Ph Ph
34 72
DCC, HOBt, NH4OH
THF
 
Synthesis of (R)-tert-butyl 1-amino-1-oxo-3-(tritylthio)propan-2-ylcarbamate, 72. To a solution of 
34 (2 g, 4.31 mmol), HOBT (700 mg, 5.17 mmol) and DCC (1.07 g, 5.18 mmol) in THF (10 mL) 
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was added 28% NH4OH (0.44 mL,  6.46 mmol) at 0 °C. After 2 hr of stirring at 0 °C, the reaction 
mixture was filtered through CeliteTM and the filtrate was concentrated, diluted with EtOAc, and 
washed with water and brine. The organic layer was then dried over sodium sulfate, concentrated 
and subjected to flash column chromatography to give 72 (1.95 g, 98%) as a white solid. 
 
3.6.2. Preparation of 73. 
 
CONH2BocHN
SPh
Ph
Ph 72
BocHN
SPh
Ph Ph
73
NH2
BH3.THF
THF
 
Synthesis of (R)-tert-butyl 1-amino-3-(tritylthio)propan-2-ylcarbamate, 73. To solution of 72(1 g, 
2.16 mmol) in anhy THF (5 mL) was added 1 M Borane·THF complex (5.4 mL, 5.4 mmol) at 0 °C 
and after stirring at 0 °C for 3 hrs,  reaction mixture was heated to 60 °C and refluxed for 12 hr. 
The reaction mixture was cooled to 0 °C, quenched by MeOH, concentrated, diluted with MeOH, 
and concentrated again. The concentrated oil was then subjected to water work-up pH = 8.5  
followed by flash column chromatography to afford 73 (0.58 mg, 60%). 
3.6.3. Preparation of 84. 
 
BocHN
SPh
Ph
Ph 73
NH2
BocHN
SPh
Ph
Ph 84
Fmoc-Cl, DMAP, DIPEA
DCM
NHFmoc
 
Synthesis of 84. To a solution of  73 (0.1168 gm, 0.26 mmol) in DCM, Fmoc-Cl (70.7 mg, 0.273 
mmol) was added followed by addition of DMAP (8 mg, 0.0654 mmol) and DIPEA (0.043 mL, 
0.26 mmol) was added at 0 °C and stirred for 3 h at room temperature. The reaction mixture was 
concentrated to give a crude oil. 84 was obtained as a solid by triturating the crude oil with ethyl 
acetate and hexane (0.147 gm, 85%). 
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3.6.4. Preparation of 85. 
 
BocHN
SPh
Ph
Ph
NHFmoc
84
TFA, TES
DCM
R1Br, NaOH, TBAI
EtOH 85
BocHN
R1S
NHFmoc
 
Synthesis of 85. To a solution of 84 (62.9 mg, 0.093 mmol) in DCM was added TES (12 mg, 
0.103 mmol). The reaction mixture was cooled to 0 °C. TFA (0.19 mg, 1.69 mmol) was added 
dropwise. The reaction mixture was concentrated and subjected to flash column chromatography 
affording the free thiol product which was subjected to the next alkylation without further 
purification (39.5 mg, 98.8 %). To a solution of crude thiol (31.2 mg, 0.0728 mmol) in ethanol was 
added TBAI (2.7 mg, 0.0073 mmol) at 0 °C. 2N NaOH (2.9 mg,0.00728 mmol) was added 
dropwise followed by dropwise addition of alkylating agent R1Br (28 mg, 0.0872 mmol) in ethanol. 
The reaction mixture was stirred for 3 hr and concentrated followed by water work-up at pH = 8.5.  
The organic layer was dried over anhydrous sodium sulfate and concentrated followed by flash 
column chromatography to give 85 (0.0435 mg, 89%). 
3.6.5. Preparation of 86. 
 
85
HCl Gas
1,4-Dioxane
BrCH2CO2t-Bu,
 DIPEA
DMF
HN
R1S
NHFmoc
86
t-BuO2CBocHN
R1S
NHFmoc
 
Synthesis of 86. To a solution of 85 (1.16 g, 1.71 mmol) in 1,4-dioxane at 0 °C HCl gas was 
passed for 15 min and the reaction was stirred at room temperature for 30 min. The reaction 
mixture was concentrated and dried by applying higy vaccum to give the crude amine which is in 
the HCl salt form (0.988 g, 100%). To a suspention of crude amine HCl salt (0.988 g, 1.71 mmol) 
in DMF was added tert-butyl bromoacetate (0.351 g, 1.79 mmol) at 0 °C followed by addition of 
DIPEA (0.443 g, 3.42 mmol) and tetrabutylammonium iodide (63.3 mg, 0.171 mmol). The reaction 
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mixture was stirred for 3 hr. The reaction mixture was concentrated, subjected to water work-up 
at pH = 8.5 followed by drying with anhydrous sodium sulfate, and flash column chromatography 
to obtain 86 (0.71 gm, 60%). 
 
3.6.7. Preparation of 87. 
 
N
R1S
NHFmoc
87
t-BuO2C
O
(T)
HN
R1S
NHFmoc
86
t-BuO2C
DMF
i) SOCl2, 13
 
Solution of 13 in thionyl chloride was refluxed for 2 hr, then the solution was concentrated with 
vaccum and the acid chloride was diluted with anhydrous DMF. 86 was added into the acid 
chloride solution followed by DIPEA. The reaction was stirred for an hour at room temperature 
and then heated up to 50 °C. The reaction mixture was concentrated and subjected to flash 
column chromatography to give 87 in 50% yield. After the column, 45% of 86 was recovered.
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4. Chapter Four: Synthesis of Cysteine based PNA Oligomers: Solid Phase Synthesis. 
4.1. Introduction. 
 
 
 As discussed in Chapter 2, the CPNA monomers were prepared with the protecting 
groups designed to allow oligomerization of the monomers using a solid phase synthetic strategy. 
In the 1960s, the solid-phase methodology was first developed by R Bruce Merrifield90 and it has 
been developed at a revolutionary pace. The solid phase synthetic methodology is now one of the 
key components for modern bioscience and it’s impossible to imagine same areas of science 
would have evolved over the last half century without this discovery. It has been widely used for 
peptide chemistry and many applications in organic chemistry have also been reported.  This 
chapter includes a brief history and the summary of the basic aspects for solid phase synthesis 
followed by the discussion of our experimental efforts to synthesize the CPNA oligomers with 
specific sequences.  
 
4.1.1. Historical introduction to solid phase synthesis: R. Bruce Merrifield and the solid-
phase synthesis.  
 
The inventor of the solid phase synthesis methodology, R. Bruce Merrifield, was born in 1921 in 
Fort Worth, Texas, and grew up in California where he obtained his Bachelor’s and Ph.D. 
degrees from UCLA.91  It was 1949, when he moved to the eastern part of US with a one year 
postdoctoral research assistantship offer from Dr. Wooley who was a professor at the Rockefeller 
Institute for Medical Research. During his Postdoctoral assistantship, he was involved with a 
project which studied a new bacterial growth factor, and was eventually introduced to a tedious 
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fragment synthesis of a pentapeptide. It took 11 months for him to complete the synthesis and the 
overall yield for the procedure was only 7 %. This bitter experience became a seed for the great 
invention he developed years later. He was appointed Assistant Professor at The Rockefeller 
Institution and eventually was promoted to associate professor in 1958. In 1959, Dr. Merrifield 
conceived the idea of a peptide synthesis on a solid support so that he would avoid the 
purification of the intermediates. It took about 4 years to overcome the challenges and publish a 
paper90 that unveiled the synthesis of first tetrapeptide by the solid-phase protocol. The seminal 
paper is now among the most cited papers in all of the scientific literature.91 He recognized the 
possibility of developing an automated peptide synthetic device, and later constructed the first 
automated peptide synthesizer using the solid-phase protocol that he developed. In 1984, Dr. 
Merrifield won the Nobel Prize in Chemistry for his discovery and development of the solid phase 
methodology that impacted the direction of scientific research throughout the world. In 2006, Dr. 
Merrifield died of a long suffered illness after being recognized as one of the most influtential 
scientists of the past century. 
 
4.2. Strategies of solid phase synthesis. 
 
Solid phase synthesis has several advantages over the traditional solution based method 
regardless of where it is a peptide or small organic molecule synthesis.94 First, it can be driven to 
completion by using excess amount of reagents while the solution based reaction often requires 
stoichiometric control of the reagents to simplify isolation of the intermediates. Whereas with 
SPPS, the excess reagents can be removed by simple washing. Second, a solid supported 
reaction can minimize the loss of the desired product due to its simple work-up procedure. Third, 
the solid phase synthesis can be conducted in a automated system. In fact, most of peptides are. 
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Figure 21: General scheme of SPPS. 
 
prepared by using an automated peptide synthesizer these days. Fourth, since every single resin 
bead can be considered as a micro- scale reactors, it is possible to synthesize large number of 
compounds simultaneously by parallel or serial combinatorial approaches  
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Figure 22: General scheme for the convergent SPPS. 
 
 The basic concept of the stepwise solid phase peptide synthesis is illustrated in Figure 
21.94 Generally two types of approaches are applied for SPPS. Stepwise SPPS92 is normally 
used for  to prepare small size peptides and the convergent SPPS strategies94 is often used for 
large peptides with longer sequences. For convergent SPPS, the scheme is little different than 
the traditional one and it is briefly demonstrated in Figure 22.  
 Generally, SPPS proceeds from the C terminus to N terminus. In other words, the N 
terminus is usually protected while the C terminus is being reacted. There have been only few 
cases reported where SPPS procedures allows C to N terminus synthesis.94 
 Among other protecting groups, Boc and Fmoc groups are the most widely used 
protecting groups for the N-terminus. Compared to the Boc method, the Fmoc strategy is 
relatively new. These two different methods have their own advantages over each other. One 
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must consider carefully which method would fit better for the oligomer synthesis depending on the 
composition of the sequence and the permanent protecting groups that are employed in the 
synthesis. 
 
Table 1: Comparison of the Boc and Fmoc SPPS strategies 
 Boc-SPPS Fmoc-SPPS Notes 
N –terminus 
Protecting group 
Boc group Fmoc group  
Deprotecting 
condition 
TFA 
Mildly bulky amine 
bases 
(usually piperidine) 
Repetitive TFA deprotecting 
steps often generates 
degradation of the peptides 
Common 
C –terminus 
protecting groups 
Base labile ester 
(Methyl or Ethyl) 
Acid labile 
t-Butyl ester 
Other protecting groups can 
be applied as long as the 
deprotecting condition 
doesn’t affect the other 
termini. i.e.: allylic ester. 
Cleavage 
condition 
HF or TFMSA TFA 
HF and TFMSA are 
extremely strong acids: 
There are safety concerns 
for the cleavage conditions 
in Boc SPPS. 
 
 
In Table 1, the two representative solid phase peptide synthesis (SPPS) strategies, Boc-SPPS 
and Fmoc-SPPS, are briefly compared. Many review papers have compared these two methods 
and it seems that the Fmoc strategies are usually the preferred one compared to the other one in 
terms of overall productivity as well as the purity of the final compounds.93 The problem of the 
Boc strategy is believed to be the repetitive usage of the TFA.  
 As a contrast to the SPPS which is considered as a quite established area, SPOC, the 
application of the solid-phase synthesis for organic chemistry is still in its development. The 
SPOC is one of the most active subjects in the field, it seems that more organic chemists are 
getting interested in the field since the scope of the application is almost unlimited. Even though 
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SPOC is not discussed in detail due to the limited scope of this report, one should be aware of 
the fact that there are many reviews and reports on the SPOC with very interesting ways of 
mixing the solid supports and countless organic methodologies. 
 
4.3. Solid supports for solid phase methodologies. 
 
 It is somewhat a misleading term ‘solid support’ used for the solid-phase peptide 
synthesis (SPPS) or solid phase organic chemistry (SPOC) because the polymers that are used 
in the reactions are not quite ‘’solid’’ solids but they are just insoluble polymers which could have 
reactions on the surface as well as inside their particles.94  Solid supports, commonly resins, can 
be classified depending on the matrices of the polymers; of course, the matrix dictates the 
properties of the resins. Resins can also be categorized by the external functional groups. 
Additionally it could also be divided by the strategies that the resin could support. Understanding 
the nature of the materials which support the SPPS or SPOC is definitely  helpful when choosing 
the optimum support and to design the optimum synthetic schemes.  
4.3.1. Essential factor for the solid supports. 
Table 2: Characteristics of an efficient resin.94 
Questions Ideal Characteristics 
Is the size and shape of the resin OK? 
Or is the resin physically stable? 
Yes, so the resin can be manipulated in the process. It 
must go through the transferring and filtering and so on. 
Is the resin inert to the reagents or 
solvents 
Yes, of course. 
It must be inert. 
Does it swell in the solvents? 
Yes, most of time. 
It should swell extensively so it can allow all the 
reagents to access all the reactive sites of the resin. 
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Is it possible to modify/generate the 
functional group?  
Yes, It should be readily modified, so one can use it in 
a variety of ways. 
Is the loading capacity of resin high 
enough? 
It should be considered. 
High capacity resins are not always ideal. 
 
Before discussing the class of the resins, it should be pointed out that there are characteristics94 
for the resins to act as good supports for the SPPS or SPOC and these are summarized in the 
Table 2. The resin should be physically stable and chemically inert throughout the whole synthetic 
process. As briefly mentioned in the introduction, the more swelling in the solvents, the more 
reactive sites the resin can have. The resin should be compatible with the anchor and the 
monomers. 
4.3.2. Representative Solid supports for SPPS.  
 
 Conventionally, It is wise to have a resin that gets solvated well in the organic solvents so 
all the active sites of the solid support can be accessible from its own steric barrier. For this 
reason, the resins with the minimal level of cross-linking consistent with reasonable physical 
stabilities are generally considered as the best solid supports.  
 
Table 3: Class of Resins.94 
Physical property Notes Matrix Notes 
Polystyrene(PS) Low cross-linked 
Polyacrylamide 
Hydrophilic alternative 
to PS  
PEG grafted  
(PEG-PS) 
 
Gel-type supports 
Most widely used 
supports. Good 
swelling, inert, flexible 
polymer network. 
PEG   
Sintered polyethylene  
Cellulose fibers  
Surface-type supports Hard surface, less (or) 
no swelling and fast 
reaction Highly Cross-linked 
PS  
Non-swelling, rapid 
reaction. 
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Pore glass, silica  
Composites and 
supported gets 
Increased mechanical 
stability 
Highly Cross-linked 
PS(exterior) + 
polyamide(interior) 
 
Brush polymers 
Linear components 
attached to a film or 
tubing 
PS grafted onto 
polyethylene 
 
 
As they are classified in Table 3, along with its hybrid forms, gel-type supports are the most 
widely used resins for SPPS and SPOC. They normally have adequate reaction rates due to their 
good swelling property and they are also physically stable. In contrast to gel type solid supports, 
resins with hard surfaces don’t swell much in organic solvents. These types of resin can have 
higher reaction rates; however they often are inefficient. Therefore these resins are often used for 
SPPS and SPOC.  
 
4.3.2.1. Polystyrene based resins 
 A suspension polymerization of styrene and divinylbenzene (DVB) provide cross-linked 
polystyrene as hydrophobic beads. The size of the bead can be controlled and virtually 
monodispersed sized beads are usually the product.94 There are two ways of functionalizing the 
resins: either by adding fuctionalized monomer for the polymerization or by functionalizing the 
polymer. The first method is not usually used because it is hard to control the polymerization this 
way. In addition, more of the functional groups may be located in positions that are sterically 
hindered so it would be difficult for them to react with the substrates. Therefore, the direct 
derivatization has been most common strategy for solid phase methodology. Electrophilic 
aromatic substitution reactions of the styrene ring of the resin, especially Friedel-Crafts 
alkylations are the main approaches for initial fuctionalization. 
In Figure 23, Figure 24, Figure 25 and Figure 26, the simplified procedures for the preparation of 
common PS resins are summarized.94 These procedures are adapted from reference 94. 
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Figure 23: Preparation of common PS resins.94 
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Figure 24: Preparation of common PS resins B.94 
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Figure 25: Preparation of common PS resins C.94 
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Figure 26: Preparation of common PS resins D.94 
 
4.3.2.2. Polyethylene glycol based resins. 
 
 Polyethylene glycol (PEG) is often used as a solid support for synthesis and also is used 
to modify the PS resins by grafting it on the functional groups of the PS resins to improve the 
properties of the solid supports. The lengths of PEGs that get grafted onto PS resins can vary 
depending on the purposes. The lengthy grafted PEGs on PS resins are often considered as 
spacers between the polymer supports and the substrates. The compositon of the PEG-PS resins 
can change the physical properties of the resin. Modifying the functional groups on the PEG-PS 
resins is also as common as that of PS based resin. Various types of linkers have been 
introduced to the PEG-PS solid supports and they are illustrated in Table 4.  
  
 
  85
Table 4: Functionalized PEG-PS resins. 
PS PEG OCH2CH2Br
 
PS PEG NHCO
OH
 
PS PEG OCH2CHO
 
PS PEG O
OH
 
PS PEG O
NH2
O
O  
PS PEG NHCO(CH2)4O
OH
O
PS PEG OCH2CH2SH
 
PS PEG OCH2CH2NH2
 
PS PEG OCH2CH2COOH
 
PS PEG OCH2CH2OH
 
PS PEG CO(CH2)2CO N
O
O
 
PS PEG NHCOCH2O
OH
 
PS PEG NHCO OH
 
PS PEG OH
X
X
X = H, Cl
 
PS PEG NHCO(CH2)nO
O
NHFmoc
 
PS PEG NHCOCH2O
NHFmoc
O
O
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Figure 27: Polyethylene glycol based resins. 
 
 PEG based resins also can be utilized as solid phase supports. The PEG molecules have 
an amphipathic nature, so PEG based resins are well solvated in both polar and nonpolar 
solvents.95 There are mainly four types of PEG based resins; PEGA resins, polyoxyethylene-
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polystryrene (POEPS) resins, Polyoxyethylene-polyoxypropylene (POEPOP) resins and cross-
linked ethoxylate acrylate resins (CLEAR). Their structures are shown in Figure 27. 
 
4.3.3. Ananyltical methods for SPPS. 
 
 There are several methods to determine whether the coupling was efficient in SPPS. The 
most widely used qualitative method is the Kaiser Test. This method is also called the nynhydrin 
test. The Kaiser test indicates the whether free primary amines are present or not by the color 
development following the procedure. It should be noted that the Kaiser test sometimes give a 
false negative sign when the resins and substrates are severely aggregated. There is another 
qualitative method known as the chlorine test. This test indicates the presence of secondary 
amines. When the solid phase synthesis is uses the Fmoc group as protecting group, it can be 
quantitatively tested using the Fmoc test. This is a good method to monitor the solid phase 
synthesis. The authors have found the fact that there are at least too procedures available for 
monitoring Fmoc group. After using both Fmoc monitoring procedures, It was learned that the 
procedure from the catalog of the Novabiochem93 gave consistent result compared to the others 
reported. Therefore, the procedure from Novabiochem is reported for our CPNA results.  
 
4.3.4. Peptide coupling methods. 
 
 The amide bond formation is the key step for the peptide synthesis and other organic 
synthetic projects as well. Therefore, there are hundreds of coupling reagents that are 
commercially available these days. In addition, the ester formation may also share the protocol 
that are prepared for amide and vice versa. The coupling techniques and reagents have been 
rapidly developed in the last few decades. This can be linked to the recent success of the peptide 
chemistry. Since peptide chemists now have access to automated peptide synthesizers along 
with the other advanced analytical devices, large numbers of peptides and even longer peptides 
are becoming available. The amide formation step should proceed to essentially 100 % yield. The 
  88
epimerization of monomers and other side reactions in the process of using the certain activating 
reagents have been an issue. Nevertheless, the activating group or the coupling reagent must be 
chosen after a thorough examination in terms of the high coupling efficiency along with the 
potential side reactions. Fortunately, there are many activating reagents that have been 
developed, and they are extensively analyzed, and compared in the reviews.93 There are 
generally 4 types of coupling strategies currently employed in solid phase synthesis: first, using 
carbodiimides as the coupling reagents; second, forming the symmetrical anhydride as an active 
species; third, using active esters as the coupling partner; and forth, utilizing the uronium based 
coupling reagents. 
Carbodiimides are one of the most popular activation reagents of all time.92 However, it is well 
know that this family of reagents produce thee insoluble ureas in some of the solvents that are 
used in SPPS. Preformed symmetrical anhydrides have been widely used for Boc SPPS due to 
their high reactivity. They can be generated in situ by mixing two equivalents of the protected 
amino acid and one equivalent of the carbodimide reagent. The urea can be easily filtered and 
the anhydrides are ready for the coupling. Freshly generated anhydrides should be used for 
satisfactory results. A drawback for this method is the waste of the monomers. Some of the 
activated esters have been extremely useful in SPPS. Obt esters and OPfp esters are great 
examples for this category.94 The most common method of all is using one of the in situ activating 
reagents which are based on phosphonium or aminium salts in the presence of a tertiary amine 
base. These reagents are known to give fast reactions generally without side reactions. The 
simple procedures are also one of the merits for these reagents. Among all the coupling reagents 
illustrated in Figure 28, Figure 29 and Figure 30, following reagents BOP, PyBOP, HBTU, TBTU, 
HATU, PyBrOP, TSTU, and TNTU are most commonly employed for routine SPPS. 
Common bases for the coupling reactions are also grouped in Figure 31. Often times, use of an 
additive accelerates the coupling and reduces racemiazation during the coupling. Commonly 
used additives are shown in Figure 32. 
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Figure 28: coupling reagents, part A. 
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Figure 29: Coupling reagents, part B. 
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Figure 30: Coupling reagents, part C. 
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Figure 31: Commonly used bases for SPPS. 
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Figure 32: Additives for the amide coupling. 
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4.4. Synthesis of CPNA oligomers. 
 
4.4.1. Preparation for solid phase synthesis. 
4.4.1.1. Deprotection of the monomers. 
 
N
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Ph
Ph Ph
O
B
39 (T), 40 (G), 41 (C), 42 (A)
20 (T), 21 (G)
24 (T)
 
Figure 33: First generation of CPNA monomers. 
 
 A series of the PNA monomers were prepared as discussed in chapter 2.  The first 
generation of monomers was prepared to test whether the native chemical ligation method could 
be adapted to the solid phase synthesis of PNAs. Monomers prepared for this new approach are 
summarized in the Figure 33. These monomers are all in protected forms, so they need to be 
deprotected in a way that the other terminus could be still intact. Except for compound 24, all the 
other compounds are protected in the traditional ways, which are commonly used for ordinary 
peptide chemistry.  We have found an interesting procedure 96  that uses a mild trialkyltin 
hydroxide to hydrolyze the methyl ester while the Fmoc group is still protected. Considering how 
vulnerable the Fmoc group is in basic conditions, this methodology is a nice protocol because it 
could provide flexibility for designing peptide synthesis and organic synthesis. We tested the  
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Figure 34: Second Generation of the CPNA monomers & the ICPNA (T) monomer. 
 
 
Scheme 15: Deprotection of Boc monomers for Boc-solid phase synthesis. 
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protocol and it worked well for our monomer 24 as shown in Scheme 16. Before we began the 
solid phase synthesis, we had to decide which coupling procedure we would use for the solid 
phase synthesis and optimize the oligomer synthesis since PNA oligomer synthesis is not trivial.  
 
Scheme 16: Deprotection of Fmoc monomers for Fmoc-solid phase synthesis. 
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4.4.1.2. Solution based coupling of monomers. 
 
 Before conducting the solid phase synthesis, we needed to confirm the coupling of our 
monomers in solution. Therefore, we decided to check the coupling of our first generation 
monomers. 
 
Scheme 17: Preliminary study before the solid phase synthesis. 
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 In the process of deprotecting our Boc-thiazolidine monomer 20, we had figured that the 
deprotecting conditions to cleave the acetonide were harsh, and many attempts to get the fully 
deprotected compound ended up giving poor yields. Even the step by step approach didn’t give a 
satisfactory result while its first step was clean. That prompted us to change our protecting group 
for the thiol to the trityl group which can be cleaved with relatively milder conditions. After 
changing the protecting groups, we were able to deprotect our monomer 39 using TFA with an 
excess amount of EDT as a scavenger. Interestingly, the Boc group can be selectively in the 
absence of the EDT scavenger. Efficient coupling between 90 and 118 gave us the fully protected 
T-T dimer 120 with a good yield while showing the HATU and TEA protocol is good for the 
coupling of our monomers at least in the solution phase. Next, the production of 121 by coupling 
between 91 and 119 suggested that our hypothesis of using the native chemical ligation method 
is still worthy of further investigation. With this encouraging result, we decided to move on to solid 
phase synthesis stage. 
4.4.2. Solid phase synthesis using native chemical ligation. 
 
After we fixed the coupling conditions from solution-based preliminary studies, we 
decided to start solid phase experiments with the Fmoc-solid phase strategy because we wanted 
to quantitatively monitor every step to confirm the efficiency of the reaction.  
As discussed earlier, the Fmoc test is the most reliable way to quantitatively monitor the 
solid phase synthesis. With the starting materials ready, we had to choose the optimum resins as 
well. Through experimentation we learned the PNA oligomer synthesis should start with a resin 
that has a less loading capacity. 
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Scheme 18: Early trials on solid-phase synthesis. 
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Scheme 19: The attempt of a solid phase synthesis using sequential native chemical ligation. 
 
   
 In Scheme 18, several solid phase syntheses were conducted to become familiar with the 
technique. After getting used to the solid phase synthesis procedure, we obtained a good result 
on solid phase synthesis (SPS) experiment # 5 which is shown in Scheme 18. At that time, we 
have prepared the newer monomer 90 which can be easily deprotected with TFA. Hence we 
wanted to see if we could employ the monomer and our charged alkyl chain simultaneously by 
taking advantage of the native chemical ligand effect of the thiol group. The experiment is 
simplified in the Scheme 19. In this procedure, The distinctive color of the trityl cation was used 
as the proof for the coupling of the T monomer. Unfortunately, after the third T-coupling we 
weren’t able to observe the distinctive yellow color that would have appeared if the trityl group 
was present. As a consequence, we decided to simplify our solid phase synthesis, so that we 
could minimize the complexity of the solid phase synthesis because it is hard to control in the 
solid phase. Thereafter, the entire scheme including the monomer synthesis had to be changed. 
As a result, our new solid phase synthesis scheme was simplified and  became more like 
conventional SPPS. However, in contrast to the solid phase synthesis, the scheme for the 
monomer synthesis became more complex because we needed to introduce the charged alkyl 
chains on the thiol of the backbone. Thereafter, we developed a novel protocol which reduces the 
racemization of the cysteine as discussed in Chapter 2. We have prepared the second generation 
CPNA monomers with both Fmoc and Boc protecting group. Therefore, we resumed the solid 
phase synthesis.  
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?
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Scheme 20: SPS with the S-alkylated monomers. 
 
4.4.3. Solid phase synthesis using S-alkylated monomers. 
 
Scheme 20 Scheme 20 shows the early experiments with the new monomers which now have 
the alkyl group attached already, so the procedures for the solid phase synthesis are simpler. 
SPS #6 shows our experiments on the Rink-amide Am resin to see where we can put our 
monomers consistently.   
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Scheme 21: Optimizing the solid phase synthesis for CPNA oligomers. 
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The first two attachments gave similar yields but the yield for the third T attachment dramatically 
dropped.  It is known that with high loaded resin, aggregation of the chain sometimes occur when 
the chain gets longer. So, we concluded that we need to use a resin with low loading capacity.  
SPS #7 in Scheme 20 employed a Sieber resin which has very low loading capacity. So we 
examined two different coupling conditions on this resin. The HATU and DIPEA condition gave 
slightly better yields on the first coupling of R1 alkylated monomer compared to the conditions 
employing DIPCDI with HOBt as additives. Nevertheless, both conditions gave excellent coupling 
efficiency and we were very excited with the result. Thereafter, we wanted to see coupling 
efficiency of other monomers. As experiment SPS #9, the first coupling of the alkylated C 
monomer gave little lower yields than the T monomer, but the second and third coupling gave us 
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consistent results with no fluctuation. Again, this data shown in Scheme 21 was very encouraging. 
The T-T dimer was also successfully employed on the Sieber resin but this time the yield was a 
little lower. 
 
Scheme 22: Employing the spacer on the resin. 
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b) 111, HATU, DIPEA
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So we came up with the idea that if we put a little more space between the linker and the start of 
the PNA with a linear alkyl chain, the yield could be improved and this could possibly reduce the 
aggregation of the oligomers. So, we purchased a simple alkyl chain which contains six carbons. 
The experiment SPS #10 shows the result of the reaction. The spacer was employed with a 
quantitative yield which was expected. The result of the next coupling with T wasn’t perfect but 
still it’s better than that of SPS #9.   
To briefly summarize, we now know that low loaded resin, such as the Sieber resin and PAL-PS-
PEG resin and HATU are the optimal conditions, and employing a spacer also increases the yield 
at least in the beginning. Therefore, we concluded that we were ready for a CPNA 15-mer 
synthesis. We had the peptide synthesizer set up and started the automated solid-phase 
synthesis using the instrument. The sequence of the 15-mer is shown in the Scheme 23. We 
actually don’t know how much of the alkyl chain would give the best properties for our oligomer. 
We decided to put the alkyl chains on every other unit first. Eventually, we want at least 3 
different compositions of the alkyl group with the same sequence so we can compare each other. 
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It took about 2 days from the day we set the experiment to figure out that the synthesis of PNA, 
especially with our bulky units, is not a trivial task. It was convenient and time-efficient to utilize a 
automated peptide synthesizer. After the entire coupling steps, we just cleaved the product from 
the resin and analyze it. Unfortunately, the MALDI-TOF spectrum of our crude product did not 
show any peaks corresponding to our desired product.  
 
Scheme 23 : Fmoc-SPS of the CPNA 15-mer on a peptide synthesizer. 
SPS # 11 : Using Peptide synthesizer.
PS PEG PAL-NHFmoc
SPACER,TGTGGCGCGCTGGGA
B : SMe monomers
B : R1 Monomers
coupling: HATU, DIPEA ?
MALDI-TOF
Suggested No product
Obtained.
What did we get?
C-terminus N-terminus
 
 After failing to obtain the CPNA 15mer with about 50 % of charged alkyl chain, we didn’t 
have any other option but do the synthesis manually and check the coupling step by step to figure 
out where and what have caused the problem. A manual synthesis of the 15-mer initiated, 
However, after the second step, we monitored that the yield dramatically decreased. So we 
thought that the alkylated G monomer was giving us problem. The G monomer we used so far 
was the O-benzyl protected one which is actually in a partially protected form. After several 
control experiments, we figured that the G monomer was giving us poor coupling consistently. 
Therefore, the acetic acid derivative of the nucleobase G had to be protected differently. We 
decided to use the conventional G protecting group which is the Cbz group. As shown in Scheme 
27, the procedure for the Cbz protected nucleobase 122 was adapted from the precedented 
paper97 and the procedure for preparation of monomers using 122 was straightforward since the 
protocols were already well established from our lab. Meanwhile, we have tried the other  
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Scheme 24: manual solid phase synthesis with G unit. 
PS PEG PAL-Spacer(Fmoc)
SPS # 12 : Manual SPS
i) 111 ii) 104
Subs : 0.18 mmol/g
HATU, DIPEA
Subs T-G : 0. 082 mmol/g
         T-G : 0. 075 mmol/g(double G)
a)
c) PS PEG PAL-Spacer(Fmoc) i) 111  ii) 111
Subs : 0.18 mmol/g
HATU, DIPEA
x 2 +
T-G(Fmoc)
Subs T-T : 0. 143 mmol/g
T-T(Fmoc)
HATU, DIPEA
d) 105
Subs T-T : 0. 06 mmol/g
T-T-C(Fmoc)
+
b) PS PEG PAL-Spacer(Fmoc)
i) 111 ii) 104
Subs : 0.18 mmol/g
HATU, DIPEA
Subs T-G : 0. 032 mmol/g
+
T-G(Fmoc)
Microwave
40 W, 4min
 
supporting material for our SPS such as a long PEG polymer and silca gel based resin as shown 
in Scheme 26. The silica gel supported resin was confirmed to be a poor supporting system for 
long sequences. However, we had a quite interesting result on the PEG polymer. Using this PEG 
polymer is actually completely different than the conventional solid-phase synthesis. It is actually 
a method that uses the unique solvation property of the certain lengths of PEG polymer. The PEG 
polymer we used has molecular weight around 5000. The polymer is soluble in MC but not in 
other organic solvents. So actually the reaction takes place in a solvent system that dissolves all 
the reagents including the PEG polymer, and then by adding the solvents that could precipitate 
the polymer which now has a unit attached. This type of strategy is called ‘liquid phase syntheses. 
It is not widely used but it could be useful for a difficult peptide synthesis because the coupling 
reaction is taking place in a homogeneous system. 
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Scheme 25 : Liquid phase synthesis and silica supported synthesis. 
OMe-PEG-NH2
M.W. : ~ 5000
SPS # 13
HATU, DIPEA
Fmoc-Rink-Linker H
N Rink-FmocPEGMeO
111
a)
 Silca-NH2
Subs : 1. 7 mmol/g
HATU, DIPEA
Fmoc-Rink-Linker
Solvent
c)
HATU, DIPEA
Solvent
H
N Rink-FmocSilica
Subs : 1. 7 mmol/g HATU, DIPEA
Fmoc-Rink-Linker H
N Rink-FmocSilica
b)
Subs : 0.33 mmol/g
Subs : 0.042
HBTU, DIEA
NMP
Fmoc-Ala-OH
H
N RinkSilica
Subs : 0.11 mmol/g
Ala(Fmoc)
H
N RinkPEGMeO T(Fmoc)
Subs: 0.13 mmol/g
 Silca-NH2
 
 
Moreover, since the PEG polymer is linear, there shouldn’t be an aggregation problem which can 
be observed in a SPPS. The coupling efficiency can be analyzed by Fmoc Test when the unit has 
the Fmoc protecting group. We figured that the efficiency of the coupling in liquid phase synthesis 
could also well be observed by the MALDI-TOF spectroscopy. 
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Figure 35: Comparison of the two mass spectra(MALDI-TOF) from PEG before (top) and 
after (bottom)the coupling of the Rink linker. 
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Figure 35 shows the distinctive spectra obtained from the PEG before the coupling and after the 
coupling of the Rink linker. Unfortunately, we weren’t able to afford the amount of the monomers 
to do this experiment repetitively. 
 
Scheme 26: Optimization of the SPS protocol. 
PS PEG PAL-Spacer(Fmoc)
i) 111 ii) 108
Subs : 0.18 mmol/g
HATU, DIPEA
Subs      T: 0.13  mmol/g
          T-G : 0. 067mmol/g
a)
+
T-G(Fmoc)
Subs spacer-T : 0. 145 mmol/g
Spacer-T(Fmoc)
Subs T-T : 0. 126 mmol/g
T-T(Fmoc)
b) PS PEG Sieber(Fmoc)
i) 111 x2
Subs : 0.23 mmol/g HATU, DIPEA Subs T: 0.11 mmol/g
          T: 0.11 mmol/g(double)
T-(Fmoc)
(R2)
*different batch from 
previous experiment
c) PS PEG Sieber(Fmoc)
i) Spacer
Subs : 0.23 mmol/g HATU, DIPEA
Subs spacer : 0.23 mmol/g
Spacer-(Fmoc)
i) 111
HATU, DIPEA
i) 111
HATU, DIPEA
d) PS PEG Sieber-Spacer(Fmoc)
Subs : 0.23 mmol/g Subs spacer-T : 0. 065 mmol/g
Spacer-T-G(Fmoc)ii) 108
HATU, DIPEA
+
 
 
When the Cbz protected G monomers were ready, our target sequence was changed. The target 
sequence is shown in Scheme 28. This time we wanted to make the entire sequence with only 
the S-methyl monomers since we thought that it would be easier to get the desired 18-mer with 
the sterically less hindered monomers. So the SPS was again tried using the peptide synthesizer. 
To be able to analyze the coupling at the final stage, we skipped the final Fmoc deprotection step. 
Hence, we were able to do the Fmoc test on the resin after all the couplings. 
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Scheme 27: Cbz protected G monomers. 
NH
NN
N
O
NHCbzO
HO
122
N
NN
N
NH2O
BnO
Cl
17
FmocHN
RS
N CO2t-Bu
O
G(Cbz)
FmocHN
RS
N
H
CO2t-Bu
FmocHN
RS
N CO2H
O
G(Cbz)
R = Me
       R1 (from Scheme 9)
       R2 (from Scheme 9)
R = Me 123
       R1 124
       R2 125
R = Me 126
       R1 127
       R2 128
BocHN
RS
N CO2Me
O
G(Cbz)
BocHN
RS
N
H
CO2Me
BocHN
RS
N CO2H
O
G(Cbz)R = Me
        R1 R = Me 129
        R1 130
R = Me 131
        R1 132
 
Scheme 28: CPNA 18-mer synthesis (G: Cbz protected). 
PS PEG Sieber(Fmoc)
Subs : 0.20 mmol/g
SPS # 13 : Automated synthesis
Spacer, GGCTTGCGTGGGGCTCCG
PS PEG Sieber-Spacer-GGCTTGCGTGGGGCTCCG(Fmoc)
Subs : 0.046 mmol/g
However, after the deprotection of Fmoc and cleavage no desired product
was detected from the MALDI-TOF
All SMe Monomers G: Cbz protected
 
The substitution level turned out to be 0.046 mmol/g after 19 coupling steps. However, the 
desired peak from the MALDI spectrum could not be observed. The purities of our monomers 
were believed to be the biggest factor for the failure since we used some of the monomers 
without purification after the tertiary butyl ester deprotection using TFA or HCl gas. This 
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deprotection step is quite clean, however if it was not performed carefully or if the monomers 
have been stored for a long time we can actually see the monomers decomposing. The sensitive 
Fmoc group could cause the problem. We have purified some of the monomers with the 
recrystallization, but it should be noted that, to be able to make this type of long oligomer every 
single monomers should be perfectly clean. Even though several attempts to make the long 
oligomers have failed it is likely that we will get the oligomer soon because we now have collected 
sufficient amount of information to improve the Fmoc solid-phase synthesis of CPNA oligomers. 
The convergent solid phase strategy also can be considered for this project. 
 
4.5. Conclusion. 
 
The solid phase synthesis is one of the most useful methodologies in history of chemistry or 
science. Peptide chemistry, polyamide chemistry and normal organic methodologies are widely 
adapting this strategy as we extensively employed the solid phase synthesis methodology for our 
CPNA project. We have manipulated the Fmoc solid-phase synthesis strategy step by step to 
make CPNA oligomer which could be a water-soluble and cell permeable antisense therapeutic 
agent. Since we have figured out many important factors to improve the solid-phase protocol for 
CPNA, it’s promising that we could get the CPNA oligomers in a short period of time. We are also 
investigating the Boc based solid phase strategies and we are getting exciting results from this 
protocol. 
The procedures for the solid phase synthesis including the procedures for the analytical tests are 
discussed in the chapter five. 
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5. Chapter Five: Procedures and Experimental Data for Chapter Four. 
5.1. Introduction. 
 
All the experiments for solid-phase synthesis were carried out under argon atmosphere 
using oven dried glassware. Most of chemicals were purchased from Aldrich Chemical Co., Acros 
Organics., EMD Biosciences Inc.  When the solvents must be anhydrous, CH2Cl2, THF and 
diethyl ether were distilled over calcium hydride or proper metals. 1H (250 MHz) and 13C (62.5 
MHz) nuclear magnetic resonance (NMR) data were recorded at room temperature in CDCl3 
using a Bruker DPX 250 spectrometer unless otherwise noted. High Resolution Mass 
Spectrometry (HRMS) spectra were recorded using an Agilent 1100 Series in the ESI-TOF mode. 
Selected NMR and Mass spectra are available in the Appendix section. For compounds with 
higher molecular weights, the mass spectra were obtained using a Bruker Autoflex series in the 
MALDI-TOF mode. 
 
5.2. General procedures and data for the solution-phase deprotection of the Monomers. 
5.2.1. General procedure for deprotection of Boc protected monomers. 
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5.2.1.1. C-termini deprotection of Boc protected monomers. 
 
 
1.5 equivalents of NaOH or LiOH solution was added into a solution of protected monomer (1 
equivalent) in 5 mL mixture of water and THF (1:1) at 0 ˚C. The reaction mixture was carefully 
monitored by TLC and when the starting material was all consumed, 5 mL of EtOAc was added 
into the mixture to extract the unreacted starting material. The water layer was then treated with 
dilute HCl solution for neutralization. Adequate amounts of EtOAc was added to extract the 
desired compound from the water layer. If needed, the extraction step was repeated a couple of 
times. The organic layer was washed with brine, dried over sodium sulfate, and concentrated to 
give the deprotected monomer with excellent yields. 
 
5.2.1.2. N-termini deprotection of Boc protected monomers. 
 
S
N N
Boc
CO2Me
O
(T)20
S
H.HClN N CO2Me
O
(T)
HCl, H2O/MeOH(1/ 3)
rt, 2day
116  
BocHN
S
N CO2H
Ph
Ph Ph
O
B
90 (T), 91 (G), 92 (C), 93 (A)
BocHN
RS
N CO2H
O
B
  94  R= Me and T    95  R= Me and G
  96  R= Me and C    97  R= Me and A
  98  R= R1  and T    99  R= R1  and G
100  R= R1  and C  101  R= R1  and A
Boc Protected Monomers:
20, 21, 39, 40, 41, 42,  76,
77, 78, 79, 80, 81, 82, 83
88 ~ 101
a) NaOH or LiOH, THF/H2O, rt.
S
N N
Boc
CO2H
O
B
88 (T), 89 (G)
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a) 20 (15 mg) was dissolved in 1.5 mL of methanolic HCl solution (conc. HCl/MeOH=3/10) and 
the solution was stirred for 2 days at room temperature.  The solution was concentrated and dried 
under vacuum to give 13 mg of 116 (crude product). 
 
BocHN
S
N CO2Me
Ph
Ph Ph
O
N
HN
O
O39
ClH.H2N
S
N CO2Me
Ph
Ph Ph
O
N
HN
O
O
90%
118
HCl(g), Dioxane
 
b) HCl(g) was bubbled into the solution of 39 (100 mg) in anhydrous dioxane (5 mL) at 0 ˚C for 10 
min with stirring, then the solution was allowed to slowly warm to room temperature. After 1 hr of 
stirring at room temperature, the solvent was removed in vacuo to give 90 mg of crude 118 as the 
HCl salt. The crude product was subjected to the next reaction without further purification. 
 
BocHN
S
N CO2Me
Ph
Ph Ph
O
N
HN
O
O39
HS
N CO2Me
O
N
HN
O
O
F3CCO2H.H2N
TFA, H2O, Triethylsilane
119
 
c) 39 (100 mg) was stirred in 2 mL of TFA/H2O (9/1) solution for 30 min and then triethylsilane (1 
eq) was slowly added and stirred until the yellowish solution became clear.  TFA was removed 
under reduced pressure and the product was diluted in 5 mL of water. The solution was washed 
with hexane and concentrated to give 85 mg of crude 119.   
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5.2.2. General procedure for deprotection of Fmoc protected monomers. 
5.2.2.1. C-termini deprotection of Fmoc protected monomers (for t-Bu ester). 
FmocHN
MeS
N CO2H
O
B
111 (T), 112 (G), 113 (C), 114 (A)
FmocHN
S
N CO2H
N
H
O
N
HCbzHN
CbzN O
B
107 (T), 108 (G), 109 (C), 110 (A)
FmocHN
S
N CO2H
N
H
O
CbzHN
O
B
103 (T), 104 (G), 105 (C), 106 (A)
N
S
NHFmocHO2C
O
H
N
O
CbzHN
B
115 (T)
Fmoc protected Monomers:
25, 58, 59, 60, 61, 63, 64, 
65, 66, 68, 69, 70, 71, 87
102 ~ 115
(R1) Fmoc monomers (R2) Fmoc monomers
(SMe) Fmoc monomers Inverted-(R1) Fmoc T-monomer
a) TFA/DCM, 1hr, quantatative
b) HCl(g), 1,4-Dioxane, 0 °C to rt. 3hr. quantatative
a or b
 
General procedure for deprotecting t-Bu esters:  
a) To a solution of a t-butyl protected monomer (0.018 mmol) in DCM (0.5 mL) was added TFA (1 
mL). After stirring at room temperature for 2 h, the reaction solution was concentrated and diluted 
with EtOAc, washed with brine, dried over sodium sulfate, and concentrated in vacuo to give a 
deprotected monomer in carboxylic acid form (quantitative yield). 
 
b) To a stirring solution of a t-butyl protected monomer (0.018 mmol) in 1,4-dioxane at 0 oC, HCl 
gas was bubbled in for 30 min. The solution was warmed to room temperature and stirred for 2 hr. 
The suspension was then concentrated over high vacuum to give the deprotected monomer. 
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5.2.2.2. C-termini deprotection of Fmoc protected monomers (for methyl ester) 
 
N
S
Fmoc
N CO2Me
O
B
N
S
Fmoc
N CO2H
O
B
102 (T)24 (T)
Fmoc methyl ester
 monomer, 24
a
102
a) Me3SnOH, DCE, 24 hr. 85%
 
24 (22 mg) was dissolved in 2 mL of DCE and 5 eq of Me3SnOH was added and the mixture was 
heated for a day. The mixture was concentrated and taken up in EtOAc. The organic layer was 
washed with brine and dried over sodium sulfate.  Removal of the solvent in vacuo afforded 15 
mg of the crude carboxylic acid, 102. 
 
5.2.3. Procedures for solution based preparation of CPNA Dimers. 
5.2.3.1. Procedures for Boc protected CPNA T-T dimer. 
 
90(T) + 118(T)
HATU, TEA
DMF
BocHN
S
N
Ph
Ph Ph
O
T
H
N
S
N CO2Me
Ph
Ph
Ph
O
T
O
120
 
TEA (50 mg) was added into the solution of 75 mg of 90, 90 mg of crude 118 and 60 mg of HATU 
in DMF (1 mL) with stirring. After 2 hr, the solvent was removed under reduced pressure. The 
residue was diluted in EtOAc and washed with water and brine. Organic layer was dried over 
sodium sulfate, concentrated and subjected to a flash column chromatography to give 110 mg of 
120 in a 75 % yield (Rf = 0.3, MeOH/DCM = 1/9) 
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5.2.3.2. Procedures for Boc protected CPNA T-G dimer (Native chemical ligation).  
 
91(G) + 119(T)
HATU, TEA
DMF
BocHN
S
N
Ph
Ph Ph
O
(BnO)G
H
N
HS
N CO2Me
O
T
O
121  
 
The same procedure as that of 120 was applied to obtain 121. 
 
 
5.3. General procedures for the solid-phase synthesis. 
 
Generally, our solid phase synthesis was performed by the following steps: 
 
 Swelling, washing, deprotecting the N-terminus, washing, coupling (double coupling as 
necessary), washing, analytical test as necessary (Kaiser test and/or Fmoc test), and repeating 
these step-wise cycles as many times as it is needed. Before the cleavage, deprotecting the N-
terminus was performed. Finally cleavage from the resin using appropriate conditions depends on 
the type of the resin. After the work-up, the product was subjected to analysis (usually mass 
spectroscopy in MALDI-TOF mode). Details of the each step are described in this section. 
 
5.3.1. Selection of Solvents. 
 
For our Fmoc protocol, we mostly used N-methylpyrrolidine (NMP). All of the resins we used 
showed great swelling properties in NMP. However, For the Boc strategy, we have used a 
mixture of DCM and NMP. For the washing step, DCM and NMP were alternatively used 
repeatedly. 
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5.3.2. Deprotecting N-terminal protecting group 
 
5.3.2.1. Deprotecting N-terminal Fmoc group 
After making sure the resin was swelled for a sufficient time, 20 % piperidine solution in DMF was 
added for 10 min with bubbling under argon gas. And this was repeated one more time. After the 
deprotection, the washing step was done immediately.  
 
5.3.2.2. Deprotecting N-terminal Boc group 
After swelling resin, 50 % TFA in DCM was added to the resin for 30 min. 
5.3.3. Coupling of a monomer or spacer using HATU activation. 
 
Generally, 3.8 equivalents of HATU and 8 equivalents of the DIPEA were premixed in the 
minimum amount of the NMP, and the mixture was immediately added to the solution of 
monomer (4 equivalents) in NMP. The mixture was then agitated for a minute, then immediately 
added onto the resin. The reaction vessel was bubbled with argon for about 30 minutes at room 
temperature, and washed thoroughly after the coupling step. Double coupling was executed as 
necessary by repeating the coupling procedure without deprotecting the N-terminal protecting 
group.  
 
5.3.4. Cleavage from the resin. 
5.3.4.1. Cleavage procedure for the Sieber resin. 
 Before the cleavage, removal of the N-terminal Fmoc group was performed. 
The cleavage procedure which adapted from Novabiochem catalog as described below: 
 
  1. Swell the resin (1 g) in DCM in a sealable sintered glass funnel and remove excess DCM. 
  2. Add 1 % TFA in dry DCM (10 mL). Seal funnel and shake for 2 min. Filter solution by applying   
pressure into a flask containing 10 % pyridine in methanol (2 mL). 
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  3. Repeat step 2 up to 10 times, wash the residual protected peptide from the resin with 3 x 30 
mL DCM, 3 x 30 mL, MeOH, 2 x 30 mL DCM, 3 x 30 mL MeOH, and check filtrates by TLC or 
HPLC. 
  4. Combine filtrates which contain product and evaporate under reduced pressure to 5 % of the 
volume. Add water (40 mL) to the residue and cool mixture with ice to aid precipitation of the 
product. 
  5. Isolate product by filtration through a sintered glass funnel. Wash product three times with 
fresh water. Dry sample in a desiccator under vacuum over KOH. 
 
5.3.4.2. Cleavage procedure for the PAM resin. 
 
1. Place the resin (250 mg) in a round bottom flask with a stirring bar and cool in an ice bath to 
between 5 °C and 0 °C.  
2. Add 250 μL of m-cresol, 50 μL EDT, 750 μL DMS and 1.25 mL of TFA, add 250 μL of 
TFMSA drop-wise to the reaction mixture with stirring to dissipate any heat produced. 
3. Allow the mixture to react for 3 h, keeping the temperature between 0 °C and 5 °C. 
4. Transfer the contents of the flask to a medium sintered glass funnel and wash the resin with 
several volumes Et2O and suction dry. 
5. Dry the resin under vacuum for a minimum of 4 h over KOH. 
6. Place the dried resin from above in a round bottom flask with a stirring bar and add 250 μL of 
thioanisol and 75 μL of EDT and stir for 5-10 min. 
7. Cool to 5 °C to 0 °C using an ice bath and add 2.5 mL of TFA.  Mix 5-10 min followed by 
addition of 250 μL of TFMSA dropwise with mixing to dissipate heat. 
8. Remove the flask from the ice bath and allow reaction to proceed at rt for 30 min with PAM 
resins for complete cleavage. 
9. Remove the resin by filtration under reduced pressure. Wash the resin twice with TFA. 
Combine filtrates and add (dropwise) and 8-10 fold volume of cold ether. 
10. Isolate the product as described in the section below. 
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5.3.5. Post cleavage work-up. 
 
The product work-up after the cleavage was executed by either precipitation or centrifugation. 
 
a) Precipitation: Filter the precipitated product through a filter paper in a Hirsch funnel under a 
light vacuum. Wash the precipitate further with cold ether, dissolve the peptide in a suitable 
aqueous buffer and lyophilize. 
b) Add a small volume of diethyl ether to the residue and triturate thoroughly until a free 
suspension is obtained. Transfer the suspension to a clean centrifuge tube, seal and 
centrifuge. Carefully decant the ether from the tube. Repeat the ether wash as necessary. 
Dissolve the residual solid in a suitable aqueous buffer and lyophilize. 
 
5.4. Analytical procedures for solid phase synthesis. 
5.5.1. The procedure for Kaiser Test. 
The procedure was adapted from Novabiochem catalog 2006/2007 version. 
 
a) Preparing the solution 
   - Dissolve 5 g of ninhydrin in 100 mL ethanol. 
   - Dissolve 80 g of phenol in 20 mL of ethanol. 
   - Add 2 mL of a 0.001 M aqueous solution of potassium cyanide to 98 mL pyridine. 
b) Testing 
   - sample a few resin beads and wash several times with ethanol. 
   - Transfer to a small glass tube and add 1 drop of each solution and leave for 5 min. 
   - Wash the beads with DMF to remove the red solution. A positive test is indicated by red beads. 
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5.5.2. The procedure for Fmoc Test. 
The procedure was adapted from Novabiochem catalog 2006/2007 version. 
 
a) Preparing sample 
   - Take 3 x 10 mm matched silica UV cells. 
   - Weigh dry Fmoc amino acid-resin (approx. 5 μmol with respect to Fmoc) into a 10 mL 
graduated flask. Add 2 mL of 2 % DBU in DMF. Agitate gently for 30 min. Dilute solution to 10 
mL with acetonitrile. Take 2 mL of this solution and dilute to 25 mL in a graduated flask. 
   - Prepare a reference solution as in step above, but without addition of the resin. 
   - Fill two cuvettes with 3 mL of test solution and one cuvette with 3 mL of reference solution. 
 
b) Testing the sample 
   - Place the cell in a spectrophotometer and record optical density at 304 nm. 
   - Obtain an estimate of first residue attachment from equation below. 
   - Substitution Level: mmole/g = (Abssample- Absref) X 16.4 / mg of resin 
 
 
 
 
 
 
6. Chapter Six: Regioselective Mono Acylation of the Electronically Less Reactive Nitrogen 
of Aryl Hydrazines via Temporary Protection with Carbon Disulfide. 
6.1. Introduction. 
 
 Hydrazines are an important class of compounds that contain the reactive nitrogen-
nitrogen bond. Hydrazines and analogues such as, hydrazides and hydrazones, are well known 
for their highly active biological profiles.98 For example, a substantial number of hydrazines and 
their analogues are known to have antineoplastic activity.98 Hydrazines are also frequently used 
in synthetic chemistry to make pyrazoles,99 oxadiazoles,100 triazoles101 and indoles.102 However, 
alkylating and acylating hydrazines can be cumbersome especially when one needs to selectively 
acylate the electronically less reactive nitrogen of the hydrazine. The early part of this chapter 
discusses the general properties of hydrazines and several examples that utilize the hydrazines 
or hydrazine derivatives as synthetic intermediates. The latter part of this chapter describes the 
developing story of a methodology which allows mono-acylation of arylhydrazines with good 
regioselectivities.  Remarkably, our protocol facilitates mono-acylation particularly on the less 
nucleophilic nitrogen of aryl hydrazines. 
 
. 
R
H
N
NH2
H
N
NH2
R
O
R3
H
N
N R2
R1
Hydrazines Hydrazides Hydrazones
 
Figure 36: Derivatives of Hydrazines  
  122
6.2. Diverse biological properties of hydrazines. 
Hydrazines are well-known for their diverse biological properties but especially for their toxicity.  
In some cases, it is believed that they are specifically toxic to the liver or the eye. Therefore, 
some hydrazines were designated as “liver” or “eye” toxins by early researchers.103  According to 
the literature,98 most hydrazines are carcinogenic in experimental animals. Hydrazines are often 
carcinogenic with about 80 of 90 hydrazines having carcinogenic activity. Nonetheless, the point 
of discussing this data is to stress on the biological activity of hydrazines. In fact, it is well-known 
in cancer research that cancer induction and cancer inhibition often times occur simultaneously. 
The best examples to support this idea are the early chemotherapeutic agents, such as mustard 
gas and other alkylating compounds. Furthermore, some drugs that are presently used, such as 
bischloroethyl nitrosourea, cyclophosphamide, chlorambucil, etc. also are known to induce and 
inhibit cancer simultaneously.98 The original idea to use hydrazines as cancer chemotherapeutic 
agents was developed by Simon in 1952 in Germany where he used hydrazine and isonicotinic 
acid hydrazide, and a series of phenyl hydrazine and thiosemicarbazide derivatives for the 
treatment of mouse ascites tumor.104 Since then, more than 400 hydrazine derivatives have been 
studied for antitumor activities in both humans and animals. Among those 400 compounds, a 
substantial number of compounds have been found to show anticancer activities for a variety of 
tumors.98 Interestingly, two hydrazine-containing natural products both cultivated from edible 
mushrooms, Agaricus bisporus and Leninus edodes, have shown antineoplastic activities in 
animals. However, these compounds were not further investigated to see if they have cancer-
inhibiting properties due to their hydrazine content.98 The most important antineoplastic drug of 
the hydrazine class used in humans is N-isopropyl-α-(2-methylhydrazino)-p-toluamide HCl 
(procarbazine, Natulan). This drug was used in combination with other compounds and with 
irradiation for a variety of neoplasms including Hodgkin’s disease. 105  A review paper which 
summarized those studies for over 400 hydrazine based compounds98 suggests that it is 
conceivable to look for a cure for cancer from the hydrazine class of chemicals. Later in this 
chapter, new aryl hydrazine derivatives are synthesized by a novel protocol that has been 
developed in our laboratory. 
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6.3. Practice of the hydrazines and their derivatives in the synthesis. 
Scheme 29: Representative reactions of hydrazines. 
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Hydrazines readily react with ketones and aldehydes to give hydrazones and this allows one to 
detect or even quantitatively analyze the concentration of the ketones and aldehydes. Hydrazine 
and its derivatives including hydrazine and hydrazone are often used for the well-known organic 
procedures; such as the Shapiro reaction,106 the Bamford-Stevens reaction,107 the Wolff-Kishner 
reduction,108 the Fischer-indole synthesis102 and the Gabriel synthesis.109 Hydrazines are also 
frequently used to make heterocyclic systems; such as pyrazoles,99 oxadiazoles,100 triazoles101 
and indoles.110 The hydrazine class of compounds very useful intermediates for the synthesis of 
natural products.111 Some of the representative reactions are illustrated in the Scheme 29 to 
highlight the usefulness of hydrazines.  
 
Scheme 30: Hydrazines as synthetic intermediates for the synthesis of indomethacin and its 
derivatives. 
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 Scheme 30  is a summarized procedure that enables the synthesis of indomethacin and 
its derivatives. The synthesis uses the Fischer indole synthesis. The synthesis involves 
protection-deprotection schemes of the hydrazine that it relevant to the new protocol that we have 
developed in our laboratory. Nevertheless, as briefly shown above, hydrazines are frequently 
used to make other interesting classes of compounds. 
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6.4. Regioselective mono acylation of the electronically less reactive nitrogen of aryl 
hydrazines via temporary protection with carbon disulfide. 
 
  As we discussed early in the chapter, hydrazines are an important class of compounds that 
are often used as synthetic intermediates. However, alkylating and acylating hydrazines is 
cumbersome especially when one needs to selectively acylate the electronically less reactive 
nitrogen of the hydrazine. For that reason, in general, alpha-acylated aryl hydrazines are much 
less readily available than the beta-acylated aryl hydrazines. In this chapter, we disclose a simple 
one-pot protocol which allows mono-acylation of arylhydrazines with good regioselectivities.  
Remarkably, our protocol facilitates mono-acylation particularly on the less nucleophilic nitrogen 
of the aryl hydrazines. 
 
6.4.1. Developing story of our new protocol. 
 
 In 1962, Tarbell and Scharrer reported their study on the decomposition of mixed 
carboxylic dithiocarbamate anhydrides.112 They reported that this decomposition gives an amide 
and carbon disulfide as result of the decomposition and suggested a mechanism which involves a 
strained 4-membered ring transition state as shown in Figure 37. It requires additional energy 
such as heating or photoactivation to promote such a rearrangement. To the best of our 
knowledge, there have not been any reports that make use of their findings as a synthetic method. 
While we were revisiting their chemistry for one of our CPNA projects which is discussed in 
earlier chapters, we developed a hypothesis that the mixed carboxylic dithiocarbamate 
anhydrides of hydrazines would form a 5-membered transition state for an intramolecular acyl 
transfer. The rearrangement would give mono-acylated products after the loss of carbon disulfide 
as shown in Figure 37. 
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Figure 37: Mechanism of the transformations.  
 
6.4.2. Optimization of the protocol. 
 
  To test our hypothesis, our first attempt was carried out with phenyl hydrazine because it is 
simple and also it has distinctly different reactivities on the two nitrogens. It is obvious that without 
the extra base only half of the hydrazine would react with carbon disulfide to form 
dithiocarbamate and the other half would be the counter ion. Therefore, at least one equivalent of 
amine base is necessary to fully form the dithiocarbamate. As shown in Table 5, the first attempt 
to make the corresponding dithiocarbamate with one equivalent of carbon disulfide in the 
presence of the DIEA at room temperature followed by slow addition of the benzoyl chloride into 
the mixture at 0 oC gave the desired product but with poor yield (Table 5, Entry 1). In fact, the 
major product of the reaction was the di-acylated compound and more beta-acylated compound 
than alpha-acylated compound was formed.  
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Table 5: Optimization of the protocol. 
H
N
NH2
Base, CS2
THF
Ph Cl
O
N
NH2
O Ph H
N
N
H
Ph
O
N
N
H
O Ph
Ph
O
A B C
Ta Tb
 
Entry Ta Tb Ratio of (A : B : C) 
1 rt -0 oC Trace : 2 : 3 
2 rt -78 oC 4 : 3 : 3 
3 -78 oC -78 oC 10 : 1 :  Trace 
 
 
Table 6: Solvent effects on this reaction. 
H
N
NH2
CS2, DIPEA
 Solvent
CH3C(O)Cl N NH2
O
 
Entry Solvents Yields (%) 
1 THF 92 
2 DCM 71 
3 Ethyl Ether 40 
4 Ethyl Acetate 60 
 
 Our next attempt was to add the benzoyl chloride at -78 oC and that gave us more of the 
desired alpha-acylated compound but still with significant amounts of the beta-acylated product 
and di-acylated byproduct (Table 5, Entry 2). At this point, we concluded that dithiocarbamate 
formation was certainly not as selective as we expected at ambient temperature. Thereafter, we 
decided to add the carbon disulfide at -78 oC and to slowly warm up the mixture to room 
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temperature to selectively form the dithiocarbamate on the more reactive nitrogen. The reaction 
mixture was then cooled again to -78 oC  before adding benzoyl chloride to selectively form the 
intermediate which eventually transfers the acyl group to the adjacent nitrogen by intramolecular 
acyl transfer while the reaction mixture was slowly allowed to warm to room temperature (Table 5, 
Entry 3). As we envisioned, the latter condition gave the desired compound with great selectivity. 
Careful observation via thin layer chromatography indicated that the intermediates, the carboxylic 
dithiocarbamate anhydrides, are unstable at temperatures above -70 oC. We then investigated 
solvent effects as summarized in Table 6. Anhydrous THF was the best solvent for our 
methodology while DCM and ethyl acetate also gave good results. 
 
6.4.3. Scope of the protocol. 
 
Table 7: Scope of the phenyl hydrazine substrates. 
H
N
NH2
CS2, DIEA
CH3C(O)Cl
THF
N
NH2R
O
R
 
Entry Substrates Products 
Yields 
(%) 
1 
H
N
NH2
 
Ac
N
NH2
 
133 92 
2a 
H
N
NH2
 
N
NH2
O Ph
 
134 87 
3 b 
H
N
NH2
Cl •ΗCl  
Ac
N
NH2
Cl  
135 80 
4b 
H
N
NH2
Cl
•HCl
 
Ac
N
NH2
Cl  
136 72 
  129
5 b 
H
N
NH2
Br •HCl  
Ac
N
NH2
Br  
137 55 
6 b 
H
N
NH2
Br
•HCl
 
Ac
N
NH2
Br  
138 40 
7 b 
H
N
NH2
NO2
•HCl
 
Ac
N
NH2
NO2  
139 75 
8 b 
H
N
NH2
FF •ΗCl  
Ac
N
NH2
FF  
140 89 
9 
H
N
NH2
O2N NO2  
Ac
N
NH2
O2N NO2  
141 85 
10 b 
 
H
N
NH2
MeO •HCl  
Ac
N
NH2
MeO  
142 9(85 c) 
aBenzoyl chloride was used instead of acetyl chloride. b1 more equivalent  of DIPEA was used. 
cyield of the beta-acylated compound. 
 
 With the optimized conditions, we have examined the scope of the reaction with various 
phenyl hydrazines and the results are summarized in the Table 7. Reactions with free hydrazines 
generally gave better yields than the substrates with HCl salt forms (Table 7, Entries 1, 2 and 9). 
Not surprisingly, functional groups with electron withdrawing effect on the aryl groups such as 
nitro, fluoro, chloro, and bromo on the phenyl ring gave alpha acylated product as major product 
with good to excellent yields (Table 7, Entries 3, 4, 5, 6, 7, 8 and 9) while 4-methoxy phenyl 
hydrazine (Table 7, Entry 10) showed inverted selectivity most likely due to the electron-donating 
effect of the methoxy group. Indeed, we carried out a control experiment for the 4-methoxy 
substrate, and the major product of the reaction without carbon disulfide was the alpha acylated 
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product. These results support our assertion that this methodology provides selective acylation of 
the electronically less reactive nitrogen of aryl hydrazines.  
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Figure 38: Comparison of the two protocols. 
 
 Figure 38 briefly illustrates an effort to synthesize Indomethacin and its analogues by 
utilizing aryl hydrazines.111 In the Maguire procedure, a three-step sequence was needed to 
obtain the alpha acylated hydrazines. These first three steps had moderate yields and the best 
yield for three steps overall was just 32 %. In contrast, our one-pot strategy gives maximum yields 
of 92 %. With our protocol it would just require two steps to synthesize this class of indomethacin 
analogues. Therefore, our one-pot protocol merits would avoid those cumbersome procedures 
and could provide the mono-acylated products with improved yields.  
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6.4.4. Experimental procedure of the protocol. 
 
6.4.4.1. Detailed the procedure for the regioselective protocol. 
The arylhydrazines (2 mmol) were dissolved in anhydrous solvent with 2.1 mmols of DIEA (an 
extra equivalent of base was added when the hydrazine was in the HCl salt form) and the solution 
was cooled to -78 oC before adding 2 mmols of carbon disulfide. After 5 min, the solution was 
slowly warmed to room temperature over 30 min. After stirring an additional 30 min at room 
temperature, the solution was cooled to -78 oC before slow addition of the acylating reagent (2 
mmols). After briefly stirring at -78 oC, the reaction was slowly allowed to warm to room 
temperature and left at RT for 2 hours. The solution was concentrated under vacuum and the 
resulting mixture was subjected to a flash column chromatography to give the product. 
 
6.4.4.2. The analytical instruments used for the protocol. 
 
 The proton nuclear magnetic resonance (1H NMR) spectra were obtained from a Bruker 
DPX250 (CDCl3 as main solvent, sometimes CD3OD were added to enhance the solubility of the 
product) and processed using ACD 1H NMR Manager (ACDLabs Software). High Resolution 
Mass Spectrometry (HRMS) spectra were recorded using Agilent 1100 Series the ESI-TOF mode. 
The NMR and HRMS spectra are attached in the appendix. 
 
6.5. Conclusion. 
 
 In conclusion, we have developed a novel protocol that facilitates mono-acylation of 
arylhydrazines with reversed selectivity. The cheap and readily available carbon disulfide used 
herein takes the important role of temporary protecting group and promotes acylation of the 
electronically less reactive nitrogen of aryl hydrazines.  Although this mechanism is quite simple, 
we believe this protocol could be very useful for other hydrazines. In addition, it is conceivable 
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that the new compounds that are prepared by our protocol could possess interesting biological 
activity like other hydrazine compounds.  
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29 Jan 2008
Acquisition Time (sec) 6.3308 Comment  spot above-1 PROTON
Date 17 Jul 2007 01:33:52
File Name C:\Documents and Settings\Sung Wook Yi\Desktop\Hydrazine NMR\W-6-71-2\W-6-71-2_001000fid
Frequency (MHz) 250.13 Nucleus 1H Number of Transients 16
Original Points Count 32768 Points Count 32768 Pulse Sequence zg30
Solvent CHLOROFORM-D Sweep Width (Hz) 5175.98 Temperature (degree C) 25.160
12 11 10 9 8 7 6 5 4 3 2 1 0 -1 -2
Chemical Shift (ppm)
3.27 3.051.08 1.00
No.  (ppm) Value Absolute Value
1 [6.20 .. 6.50] 1.000 6.07396e+8
2 [6.80 .. 7.05] 3.053 1.85459e+9
3 [7.10 .. 7.37] 2.928 1.77868e+9
4 [7.37 .. 7.71] 3.271 1.98664e+9
5 [7.74 .. 7.89] 2.063 1.25276e+9
6 [7.92 .. 8.15] 1.083 6.58040e+8
H
N
N
H
Ph
O
N'-phenylbenzohydrazide
Chemical Formula: C13H12N2O
Exact Mass: 212.095
Molecular Weight: 212.2472
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30 Jan 2008
Acquisition Time (sec) 6.3308 Comment  polar spot Date 13 Jan 2008 06:28:16
File Name C:\Documents and Settings\Sung Wook Yi\Desktop\Hydrazine NMR\W-8-80-1\W-8-80-1_001000fid
Frequency (MHz) 250.13 Nucleus 1H Number of Transients 16
Original Points Count 32768 Points Count 32768 Pulse Sequence zg30
Solvent CHLOROFORM-D Sweep Width (Hz) 5175.98
Temperature (degree C) 21.160
12 11 10 9 8 7 6 5 4 3 2 1 0 -1 -2
Chemical Shift (ppm)
11.24 2.00
7.
24
7.
14
4.
99
No. (ppm) (Hz) Height
1 4.99 1247.2 0.3336
2 7.14 1787.1 0.4240
3 7.24 1809.9 0.3166
No.  (ppm) Value Absolute Value
1 [4.76 .. 5.17] 2.000 1.11203e+9
2 [6.77 .. 7.51] 11.240 6.24963e+9
N
NH2
O Ph
N-phenylbenzohydrazide
Chemical Formula: C13H12N2O
Exact Mass: 212.095
Molecular Weight: 212.2472
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30 Jan 2008
Acquisition Time (sec) 6.3308 Comment  PROTON Date 25 Sep 2007 23:25:52
File Name C:\Documents and Settings\Sung Wook Yi\Desktop\Hydrazine NMR\W-7-60-1\W-7-60-1_001000fid
Frequency (MHz) 250.13 Nucleus 1H Number of Transients 16
Original Points Count 32768 Points Count 32768 Pulse Sequence zg30
Solvent CHLOROFORM-D Sweep Width (Hz) 5175.98
Temperature (degree C) 25.160
12 11 10 9 8 7 6 5 4 3 2 1 0 -1 -2
Chemical Shift (ppm)
4.98 3.002.04
7.
42
7.
39
7.
26
4.
82
2.
09
2.
01
1.
61
0.
00
No. (ppm) (Hz) Height
1 -0.01 -1.6 0.1193
2 -0.00 -0.0 1.0000
3 1.61 403.7 0.4455
4 2.01 501.6 0.3918
5 2.09 521.7 0.1203
6 4.82 1205.5 0.1414
7 7.26 1816.8 0.7117
8 7.39 1848.4 0.3460
9 7.41 1854.4 0.2055
10 7.42 1855.9 0.2820
No.  (ppm) Value Absolute Value
1 [1.83 .. 2.08] 3.000 1.65127e+9
2 [4.53 .. 5.03] 2.039 1.12221e+9
3 [7.29 .. 7.55] 4.985 2.74385e+9
N
NH2
O
N-phenylacetohydrazide
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30 Jan 2008
Acquisition Time (sec) 6.3308 Comment  PROTON Date 17 Sep 2007 23:32:16
File Name C:\Documents and Settings\Sung Wook Yi\Desktop\Hydrazine NMR\W-7-55-1\W-7-55-1_001000fid
Frequency (MHz) 250.13 Nucleus 1H Number of Transients 16
Original Points Count 32768 Points Count 32768 Pulse Sequence zg30
Solvent CHLOROFORM-D Sweep Width (Hz) 5175.98
Temperature (degree C) 25.160
12 11 10 9 8 7 6 5 4 3 2 1 0 -1 -2
Chemical Shift (ppm)
3.28 3.002.59 1.72
0.
00
1.
96
3.
83
4.
80
6.
90
6.
94
7.
22
7.
27
No. (ppm) (Hz) Height
1 0.00 0.1 0.3149
2 1.96 490.0 0.7946
3 3.83 958.0 1.0000
4 4.80 1201.0 0.1415
5 6.90 1726.2 0.2555
6 6.94 1735.2 0.3244
7 7.18 1796.3 0.2214
8 7.22 1805.2 0.1798
9 7.27 1818.0 0.2600
No.  (ppm) Value Absolute Value
1 [1.86 .. 2.03] 3.000 2.02696e+9
2 [3.76 .. 3.97] 3.280 2.21592e+9
3 [4.59 .. 5.05] 1.715 1.15889e+9
4 [6.84 .. 7.07] 2.250 1.52045e+9
5 [7.09 .. 7.41] 2.586 1.74754e+9
N
NH2
O
MeO
N-(4-methoxyphenyl)acetohydrazide
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30 Jan 2008
Acquisition Time (sec) 6.3308 Date 16 Jan 2008 01:44:32
File Name C:\Documents and Settings\Sung Wook Yi\Desktop\Hydrazine NMR\W-86-2\W-86-2_001000fid
Frequency (MHz) 250.13 Nucleus 1H Number of Transients 16
Original Points Count 32768 Points Count 32768 Pulse Sequence zg30
Solvent MeOD Sweep Width (Hz) 5175.98 Temperature (degree C) 22.160
12 11 10 9 8 7 6 5 4 3 2 1 0 -1 -2
Chemical Shift (ppm)
3.033.00
7.
53
7.
11 7.
07 6.
92
6.
84
2.
39
2.
04
No. (ppm) (Hz) Height
1 2.04 510.4 0.7675
2 2.39 597.3 0.1431
3 6.84 1711.1 0.0461
4 6.92 1730.4 0.0574
5 7.07 1768.1 0.0209
6 7.11 1778.4 0.0142
7 7.53 1883.9 0.0120
No.  (ppm) Value Absolute Value
1 [1.83 .. 2.48] 3.028 4.00729e+9
2 [6.67 .. 7.76] 3.000 3.97041e+9
N
NH2
O
FF
N-(2,4-difluorophenyl)acetohydrazide
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30 Jan 2008
Acquisition Time (sec) 6.3308 Comment  4-bromo Date 18 Jan 2008 19:03:28
File Name C:\Documents and Settings\Sung Wook Yi\Desktop\Hydrazine NMR\W-8-89-1\W-8-89-1_001000fid
Frequency (MHz) 250.13 Nucleus 1H Number of Transients 16
Original Points Count 32768 Points Count 32768 Pulse Sequence zg30
Solvent CHLOROFORM-D Sweep Width (Hz) 5175.98
Temperature (degree C) 21.160
12 11 10 9 8 7 6 5 4 3 2 1 0 -1 -2
Chemical Shift (ppm)
4.20 3.001.37
7.
55
7.
52
7.
27
4.
79
2.
02
No. (ppm) (Hz) Height
1 2.02 504.0 0.5831
2 4.79 1197.2 0.1804
3 7.27 1818.0 0.6834
4 7.52 1880.5 0.5918
5 7.55 1889.2 0.4769
No.  (ppm) Value Absolute Value
1 [1.79 .. 2.51] 3.000 2.65722e+9
2 [4.43 .. 5.02] 1.372 1.21549e+9
3 [6.88 .. 7.93] 4.201 3.72105e+9
N
NH2
O
Br
N-(4-bromophenyl)acetohydrazide
Chemical Formula: C8H9BrN2O
Exact Mass: 227.9898
Molecular Weight: 229.0739
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30 Jan 2008
Acquisition Time (sec) 6.3308 Date 15 Jan 2008 07:25:52
File Name C:\Documents and Settings\Sung Wook Yi\Desktop\Hydrazine NMR\W-8-85-1\W-8-85-1_001000fid
Frequency (MHz) 250.13 Nucleus 1H Number of Transients 16
Original Points Count 32768 Points Count 32768 Pulse Sequence zg30
Solvent CHLOROFORM-D Sweep Width (Hz) 5175.98 Temperature (degree C) 22.160
12 11 10 9 8 7 6 5 4 3 2 1 0 -1 -2
Chemical Shift (ppm)
4.28 3.001.56
7.
40
7.
37
7.
27
7.
26
4.
79
2.
01
0.
00
No. (ppm) (Hz) Height
1 0.00 0.0 0.5434
2 0.00 0.7 0.4995
3 2.01 502.0 0.9379
4 4.79 1198.0 0.4215
5 7.26 1815.4 0.4711
6 7.27 1818.7 0.7425
7 7.37 1842.4 1.0000
8 7.40 1850.9 0.5670
No.  (ppm) Value Absolute Value
1 [1.81 .. 2.48] 3.000 2.94014e+9
2 [4.43 .. 5.09] 1.558 1.52685e+9
3 [7.03 .. 7.79] 4.277 4.19159e+9
N
NH2
O
Cl
N-(4-chlorophenyl)acetohydrazide
Chemical Formula: C8H9ClN2O
Exact Mass: 184.0403
Molecular Weight: 184.6229
 
 
 
 
 
 
 
 
Appendix (Continued) 
 219
 
 
 
30 Jan 2008
Acquisition Time (sec) 6.3308 Date 22 Jan 2008 10:48:32
File Name C:\Documents and Settings\Sung Wook Yi\Desktop\Hydrazine NMR\W-HZ-3nitro\W-HZ-3nitro_001000fid
Frequency (MHz) 250.13 Nucleus 1H Number of Transients 16
Original Points Count 32768 Points Count 32768 Pulse Sequence zg30
Solvent CHLOROFORM-D Sweep Width (Hz) 5175.98 Temperature (degree C) 20.160
12 11 10 9 8 7 6 5 4 3 2 1 0 -1 -2
Chemical Shift (ppm)
3.57 3.001.71
2.
18
4.
80
7.
59
7.
62
8.
148.
25
No. (ppm) (Hz) Height
1 2.18 544.5 0.6411
2 4.80 1200.8 0.0905
3 7.59 1898.5 0.2506
4 7.62 1906.6 0.1822
5 8.14 2035.0 0.1241
6 8.25 2062.5 0.1293
No.  (ppm) Value Absolute Value
1 [1.82 .. 2.76] 3.000 3.06759e+9
2 [4.13 .. 5.14] 1.705 1.74381e+9
3 [7.42 .. 8.61] 3.566 3.64612e+9
N
NH2
O
NO2
N-(3-nitrophenyl)acetohydrazide
Chemical Formula: C8H9N3O3
Exact Mass: 195.0644
Molecular Weight: 195.1754
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30 Jan 2008
Acquisition Time (sec) 6.3308 Comment  3-Chloro Date 16 Jan 2008 01:36:00
File Name C:\Documents and Settings\Sung Wook Yi\Desktop\Hydrazine NMR\W-87-1\W-87-1_001000fid
Frequency (MHz) 250.13 Nucleus 1H Number of Transients 16
Original Points Count 32768 Points Count 32768 Pulse Sequence zg30
Solvent CHLOROFORM-D Sweep Width (Hz) 5175.98
Temperature (degree C) 22.160
12 11 10 9 8 7 6 5 4 3 2 1 0 -1 -2
Chemical Shift (ppm)
4.27 3.001.74
7.
35 7
.3
2
4.
79
2.
05
No. (ppm) (Hz) Height
1 2.05 512.1 0.5858
2 4.79 1196.9 0.1983
3 7.32 1830.3 0.7235
4 7.35 1837.9 0.6934
No.  (ppm) Value Absolute Value
1 [1.77 .. 2.53] 3.000 2.78144e+9
2 [4.36 .. 5.02] 1.737 1.61076e+9
3 [7.00 .. 7.57] 4.267 3.95576e+9
N
NH2
O
Cl
N-(3-chlorophenyl)acetohydrazide
Chemical Formula: C8H9ClN2O
Exact Mass: 184.0403
Molecular Weight: 184.6229
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